
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

39138145
1891
10.1038/s41392-024-01891-4
Review Article
Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies
He Jun 12
Qiu Zejing 12
Fan Jingjing 12
Xie Xiaohong xxh666857@163.com

3
Sheng Qinsong shengqinsong@zju.edu.cn

4
http://orcid.org/0000-0001-7330-0467
Sui Xinbing hzzju@hznu.edu.cn

12
1 grid.410595.c 0000 0001 2230 9154 Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, Zhejiang 311121 China
2 https://ror.org/014v1mr15 grid.410595.c 0000 0001 2230 9154 Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121 China
3 https://ror.org/04epb4p87 grid.268505.c 0000 0000 8744 8924 Department of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang China
4 https://ror.org/00a2xv884 grid.13402.34 0000 0004 1759 700X Department of Colorectal Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang China
14 8 2024
14 8 2024
2024
9 2092 3 2024
21 5 2024
3 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Non-genetic mechanisms have recently emerged as important drivers of anticancer drug resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more and more attention and giving a predominant non-genetic role in cancer therapy resistance. The DTP phenotype is characterized by a quiescent or slow-cell-cycle reversible state of the cancer cell subpopulation and inert specialization to stimuli, which tolerates anticancer drug exposure to some extent through the interaction of multiple underlying mechanisms and recovering growth and proliferation after drug withdrawal, ultimately leading to treatment resistance and cancer recurrence. Therefore, targeting DTP cells is anticipated to provide new treatment opportunities for cancer patients, although our current knowledge of these DTP cells in treatment resistance remains limited. In this review, we provide a comprehensive overview of the formation characteristics and underlying drug tolerant mechanisms of DTP cells, investigate the potential drugs for DTP (including preclinical drugs, novel use for old drugs, and natural products) based on different medicine models, and discuss the necessity and feasibility of anti-DTP therapy, related application forms, and future issues that will need to be addressed to advance this emerging field towards clinical applications. Nonetheless, understanding the novel functions of DTP cells may enable us to develop new more effective anticancer therapy and improve clinical outcomes for cancer patients.

Subject terms

Cancer therapy
Tumour immunology
Cancer metabolism
issue-copyright-statement© West China Hospital, Sichuan University 2024
==== Body
pmcIntroduction

Resistance to anticancer drug therapy, especially first-generation targeted therapy products, is a critical bottleneck in comprehensive anticancer treatment. For example, patients with lung cancer treated with Gefitinib, a first-generation epidermal growth factor receptor (EGFR) inhibitor, typically develop resistance after 9 to 15 months of progression-free survival.1 Genetic mechanisms, such as mutations in the T790M gene,2,3 have been partially attributed to the development of drug resistance. However, evidence is increasingly pointing towards non-genetic mechanisms as playing a critical role in resistance development, with the presence of DTP cells being a key factor.4

DTP cells refer to a subgroup of cancer cells with distinct biological characteristics5 and internal mechanisms,6 allowing them to resist initial anticancer treatment. Unlike specific or characteristic cancer cells,7 DTP cells persist in the anticancer drug environment, exhibiting significant variances from typical cancer cells in aspects such as cell-cycle, micro-environment regulation, and metabolism. These differences confer upon them the ability to endure and subsequently contribute to cancer recurrence and metastasis. Currently, research on the mechanism of DTP formation and drug resistance has primarily been conducted through cellular tests,8–12 animal tests,13–16, and mathematical models.13 Some studies have likewise mentioned the potential of anti-DTP treatments.8,17,18 However, no clinical studies have yet confirmed the existence of DTP cells or the effectiveness of anti-DTP treatments following anticancer therapy in humans. The lack of quantifiable understanding of DTP and the unclear direction of its potential clinical treatment hinders further exploration. This review provides a comprehensive characterization of the biology and basic mechanism of action of DTP cells, along with descriptions of potential therapies for anti-DTP. Additionally, it extends the direction of future development and application, providing ideas and guidelines to promote this emerging field towards clinical application.

Proposed DTP: Evolution of research developments on DTP cells

Chronicle of DTP cells

The evolution of DTP research is a part of the complex and evolving field of oncology from recognition to conjecture to confirmation (Fig. 1). Soon after the discovery of penicillin antibacterial treatment, scientists noted the phenomenon of drug resistance.19–23 This initial observation indicates that adaptation of treatment plays a significant role in drug resistance,24 advancing medical understanding in this area. With the introduction of drug therapy for cancer, researchers encountered a parallel issue of cancer cells developing resistance to anticancer drugs,25 echoing bacterial drug resistance. Likewise, like antimicrobials to bacteria,26 solely producing new drugs may be sufficient to address cancer resistance. Subsequent research has focused on the genetic mechanisms associated with gene mutations27 in malignant cancer cells, offering hope for addressing drug resistance. However, the unpredictable nature of mutations prevented this from becoming the definitive solution sought by researchers.28–31 Consequently, exploring non-genetic mechanisms emerged as a promising direction, with the discovery of a drug-resistant subpopulation by Sharma et al.32 attracting significant interest. The concept of DTP cells, originating from lung cancer cells,32 initially was considered unique lung cancer cells’ transformations rather than universal cancer cells. Nonetheless, further studies8,33 on DTP cells cultured from various cancer types suggested common underlying changes shared among cancer cells. Presently, the primary focus of DTP-related research lies in identifying fundamental transition rules – essential for understanding the non-genetic mechanisms of cancer drug resistance. Leveraging these principles to redefine the defense strategies in modern medicine has become a crucial research priority within the DTP field.Fig. 1 The historical timeline of the DTP concept from the inception to the present peak. At the initial beginning, the discovery of antibiotics and the drug resistance phenomenon290 was the first critical period of human cognitive resistance (Stage 1). After recognizing cancer and traditional chemical therapy, the frequently limited effectiveness of treatment has led researchers to observe the widespread problem of drug resistance in anticancer drug therapy291–293 (Stage 2). The newly developed targeted therapy also owns the problem of drug resistance in anticancer therapy,294–297 which further deepens the thinking on the root nature of cancer drug resistance24 (Stage 3). With the initial observation of a chromatin-mediated reversible drug-tolerant state in the targeted therapy of non-small cell lung cancer,32,112,298 the concept of DTP has been proposed and its possibility has been preliminarily verified (Stage 4). Since then, more and more researchers have used the concept of DTP cell to bring several studies on its mechanism6,7,13,15,16,96,111,177,238,253,288,299–301 and treatment related8,10,17,81,97,284,287,302,303 analysis, and a variety of different mechanisms and possible solutions have filled the entire field of DTP cells research, and a spurt of development stage constitutes the present new period (Stage 5)

Latest insight into the transition of DTP cells

In the existing blowout studies, two possible origin or transformation mechanisms of DTP cells (Fig. 2) have been discussed as relatively recent concepts.4,34 The first mechanism is the clonal selection mechanism hypothesis, which pertains to primary cancer resistance. The second mechanism, namely the drug induction mechanism hypothesis, is associated with secondary cancer resistance. These two mechanisms are not mutually exclusive or contradictory; however, they differ in their emphasis and thus guide divergent lines of observation in various studies.Fig. 2 There are two primary hypotheses regarding the origin or transformation mechanisms of DTP cells and resistance to anticancer drugs: primary and secondary. Clonal Selection Mechanism (Part a): In the hypothesis of clonal selection, primary drug resistant cells with natural gene mutations, receptor/ligand changes, and effector abnormality are present within normal cancer cells and lead to cancer recurrence during external anticancer drug therapy. Drug-induction Mechanism (Part b): In the hypothesis of drug induction, the initial drug insensitive cells result from the inducing effect of anticancer drug, and lead to characteristic DTP cells during long-term drug maintenance and eventually reactivation and proliferation. Regardless of the hypothesis’s origin, DTP cells ultimately resist drug-directed cancer recurrence. (Drawn by figdraw)

Clonal selection mechanism

As the classic possible cause of cancer drug resistance,35 clonal selection is one possible mechanism that could lead to the emergence of DTP cells. This process is built on classical Darwinian principles,36 where a few persister cells may have been present before drug treatment and are subsequently selected. Due to the genomic instability of cancer cells, they may exhibit different sensitivities to drug action.37,38 This genomic instability could result in the emergence of DTP cells, which can then be screened for potential drug treatment.39 It is important to note that unstable inheritance can lead to a limited occurrence of similar phenotypes or characteristics among resistant cells, despite their common origin from the same cells, owing to genomic instability. Various studies7,40 have shown the presence of DTP cases lacking similar phenotypes and characteristics, while Raha et al.41 observed the contrary, indicating similarity in the DTP cells. Moreover, this similarity extends to holding cells resulting from the entry of cancer cells from diverse origins into the DTP cells.42

Drug induction mechanism

The second aspect is induced transformation which refers to the ability to resist treatment and withstand external drugs, environmental stresses, and other factors. In 1975, Miroslav Radman’s team discovered the existence of an inductive bacterial DNA repair/mutagenesis system (SOS response). This system is initiated in response to DNA damage, and it promotes genetic variation and reinforces bacterial resistance through the activation of transcriptional programs and genomic alterations.43–45 The stress-induced mutation (SIM) mechanism, which is associated with the SOS response, exists in eukaryotes46 and has significant implications for microbial drug resistance. Recent findings have revealed that SIMs have a role in promoting drug resistance in target organisms and can contribute to the development of resistance associated with targeted therapy. Notably, SIM has been identified as a contributing factor in acquired resistance associated with anticancer therapy, observed in diverse tumors where the therapeutic mechanism of action of the targeted drug serves as a stress-sensitive regulatory site.47,48 Furthermore, multiple studies13,49–51 have confirmed the generation of the DTP cells under drug induction, with numerous factors inducing cancer cells to transition into the DTP cells, making them a recognized potential source of drug resistance.

Non-genetic mechanism deserves more attention

The DTP cells discussed in this review pertain to a scenario where a small proportion of cancer cells gain resistance to prior treatments during oncological therapy while exhibiting comparable phenotypes or characteristics. It is uncertain whether drug-resistant cancer cells that lack genetic stability can be classified as DTP cells. To date, the clonal selection theory has not provided a sufficient explanation for the emergence of DTP, while the induced transformation theory does not clarify the presence of partially drug-resistant cells during the early stages of treatment.32 The mechanisms of both clonal selection and induced transformation are complex and contribute to the development of drug resistance in a subtle manner. Clonal selection may facilitate the initial survival of malignant cells during anticancer therapy, permitting a minority of cancer cells to acquire additional drug-resistant mutations, thereby facilitating disease progression. This ultimately leads to the survival of such cancerous cells following treatment, known as Minimal Residual Disease (MRD).52 Additionally, the process of transformation may cause a restricted population of cancer cells, initially vulnerable to drugs, to acquire drug resistance, sustaining this resistance during treatment and eventually resulting in tumor regrowth. The DTP cells mentioned above have been discovered in various types of cancerous tumor cells, including common lung cancer,53 ovarian cancer,54 melanoma,55,56 colorectal cancer33 etc. Interestingly, some DTP cells from various origins could manifest comparable phenotypes.42 Furthermore, in a separate study, Rehman et al.13 constructed a mathematical model concerning persister cells and ascertained that all cancer cells possess the ability to turn into DTP cells. However heritable mutations in cancer cells leading to resistance changes are commonly observed that cannot be overlooked. When researchers need to shift their attention to the non-genetic mechanisms of DTP cell components, the impact of these gene mutations can be particularly annoying. The pursuit to address this hybrid aspect has been a long-standing issue. It was not until the discovery of Mex3a15 and related surface antigen57 detection mechanisms that it became facilitative to better understand and differentiate DTP cells based on molecular probes and their unique characteristics.

The above evidence suggests that the DTP cells could be a frequently occurring stress response mechanism shared by cancer cells, so the non-genetic mechanism deserves further investigation.58 Of course, further studies are needed to ascertain more definitive mechanisms of DTP origin.

Discovered DTP: Guided by the change of characteristics to explore formation of DTP cells

It is challenging to investigate and delineate the formation mechanism of DTP cells owing to the absence of direct observation and recording. Nevertheless, indirect analysis serves as a viable alternative, offering a feasible approach to look into the formation mechanism. Exploring the characteristic changes that occur before and after the formation or transformation of DTP cells represents a promising starting point in this endeavor. By offering a glimpse into the distinctive biology of DTP cells, such analysis contributes to the current, albeit limited, understanding of the enigmatic process underlying the formation of DTP cells.

Summary of notable characteristics after DTP cells formation

Notably, the biological characteristics include their slow-cell-cycle properties, also known as cell-cycle restriction, their embryonic-like torpor/diapause stasis, their stem-like phenotype and plasticity, and their state reversibility. These features, which differ from those of ordinary cancer cells before transformation, are critical in shaping the nature and behavior of DTP cells (Fig. 3).Fig. 3 Notable characteristics of DTP cell transformation. Cycle Restriction (a): DTP cells concentrate in the G1 phase and do not undergo further proliferation. Embryonic-like Torpor/Diapause (b): Similar to organisms entering an embryonic-like state in response to external stimulus, DTP cells also exhibit a torpor/diapause state when stimulated by drugs in cancer cells. Stem-like Phenotype (Part c): DTP cells express some stemness markers as known cancer stem cells, such as CD133/CD166/ALDH, and have cellular plasticity. State Reversibility (d): DTP cells produced by cancer cell undergoing anticancer therapy can revert to a repopulating cancer cell state after discontinuation of drug therapy for a certain duration of time and subsequently exhibit DTP cells upon resuming treatment. (Drawn by figdraw)

Cell-cycle restriction

The DTP cells, demonstrated in multiple studies, represent a state of cellular cycle quiescence or slowing down.32,59,60 Zhang et al.33 developed a model for colorectal cancer and used 5-FU treatment to control CRC growth. They observed a subset of cancerous cells that exhibited resistance to 5-FU treatment. The study identified a distinct subgroup of cancer cells referred to as DTP cells, which demonstrated significant cell-cycle related inertness. These cells displayed uncontrolled proliferation during and after 5-FU treatment. Supplementary analysis of the cell-cycle in CRC DTP cells revealed that the majority of drug-resistant cells were in the G0/G1 phase. Meanwhile, Criscione et al.61 investigated the impact of Osimertinib treatment on acute treatment and DTP cells in non-small cell lung cancer (NSCLC). Their study found that drug-resistant cancer cells treated with Osimertinib exhibited decreased expression of cell-cycle related genes compared to DMSO. Additionally, the study revealed that a subset of cell-cycle-related pathways and genes nearly returned to baseline levels after the removal of the therapy agent. This research sheds light on the discrepancies in Osimertinib treatment’s effects and provides valuable insights into its influence on cancer cell behavior.

Embryonic-like Torpor/Diapause

As a concept parallels the survival strategies observed in nature, where organisms enter a state of reduced activity to endure difficult environments,62 some studies13,51 propose that akin to organisms adopting a conservative state of being to survive in hostile environments, such as torpor, estivation, and diapause, cancer employs a similar conservative survival strategy known as the DTP cells in response to the adverse conditions caused by chemotherapy and targeted therapy.63

Rehman et al. conducted a study13 to examine the factors influencing the DTP cells’ transition in a model of colorectal cancer. They employed various techniques, including second-generation sequencing and mathematical modeling, in their research. The results revealed that all cancer cells have an equal ability to transfer to the DTP cells and that they adopt a state parallel to embryonic stasis to withstand the effects of chemotherapy. Similar to embryonic cells, DTP cells can revert to a cancer state after the cessation of stress. When the pressure is removed, DTP cells can exit this state and develop into cancer again.64

Stem-like phenotype

Stem-like phenotype may also be a commonly shared special biological trait of DTP cells. The concept of stemness is frequently discussed with cancer stem cells, which form a subset of cancer cells responsible for sustaining malignant growth within a tumor. These cells are typically characterized by self-renewal and pluripotency, demonstrating multidirectional transformation. They can be identified through specific markers such as CD133, CD44, CD166, CD24, and ALDH. The concept of stemness has been particularly instrumental in distinguishing the direction of differentiation and the degree of malignancy across a wide spectrum of tumors.65,66

In a study conducted by Arasada RR et al.,67 residual cells with a high expression of potential cancer stem cell markers, including ALDH, were observed. These cells, which can be referred to as the DTP cells, were obtained by treating EGFR-mutated lung cancer cells with erlotinib. The researchers found that these residual cells possessed the ability to form spheres with clonal expansion potential and the condition of temporary stasis. This suggests that these cells may play a crucial role in cancer maintenance and resistance to treatment. Similarly, various other cancer types express numerous stem cell markers in DTP cells, including CD133 and CD24 in NSCLC,53,68 SOX2, OLIG2, and NFIA in glioblastoma,69 and JARID1B and CD271 in melanoma.70 In addition, colon,71 breast,72,73 prostate,74 and ovarian75 cancer also harbor “dormant cells” exhibiting a stemness phenotype. Cancer cells often exhibit stemness as an adaptive response to environmental stimuli, particularly chemotherapy, leading to the differentiation of cancer cells into various clonal subpopulations.76,77 This process is akin to the concept of cellular plasticity, which involves the acquisition of specific molecular traits through subcellular self-renewal, influenced by various intracellular pathways impacting epigenetic and transcriptional regulation. Consequently, these pathways ultimately dictate the resulting cellular behavior.32,78 In the case of melanoma cells known as the DTP cells, a transcriptional state associated with the stemness of neural crest cells emerges in response to targeted therapy,55 indicative of cellular plasticity. This phenomenon can be described as either melanoma DTP cell stemness or cellular plasticity. Consequently, several articles often draw connections between cancer cell stemness and cellular plasticity.

Reversibility of transformation

The reversibility of the DTP cells79 is a critical property, as evidenced by the observed cell-cycle inhibition and embryonic-like stasis, rather than a one-way state that cannot be withdrawn. When cancer cells enter this state, they exhibit near-stagnant behavior, allowing DTP cells to retain the potential to become active again and resume proliferation.7,80 Consequently, this resurgence is translated of drug-resistant properties and ultimately culminates in drug resistance and cancer recurrence. These observations underscore the significance of the DTP cells’ reversibility in driving the progression toward drug resistance and cancer metastasis.

In a recent study on the DTP cells in breast cancer, Chang et al.81 induced breast cancer cells to enter the DTP through the use of TKI inhibitors such as lapatinib and tucatinib. After induction, it was observed that HER2 TKI DTP cells exhibited signs of re-growth upon the cessation of TKI inhibitors. Furthermore, cancer cells exposed to diluted concentrations of TKI inhibitors showed some degree of proliferation and multiplication. Additionally, this subset of cancer cells that had transitioned back to the proliferative and reproductive state were capable of re-entering the DTP, displaying corresponding phenotypic characteristics upon treatment with the appropriate level of TKI inhibitors. These findings conclusively demonstrate that the DTP cells have reversible conditions with the ability to self-regulate in response to environmental changes. Furthermore, the reversible manifestation is not solely present in the DTP cells of breast cancer, but also in ovarian,82 colon,83 and lung84 cancer. Several sources have reported similar response patterns to retreatment after the cessation of treatment.85 These findings are discussed in Cara et al.‘s86 research, which suggests that a “seemingly drug-resistant but not drug-resistant cancer” may reflect the DTP cells’ reversibility.87

The existence of reversibility within DTP cells allows for a small number of cancer cells to persist in the body for an extended period through flexible transformation of the DTP cells, complementing the stemness or plasticity of these cells. This attribute poses significant challenges to eradicating these cells through multiple comprehensive treatments, contributing to the potential for cancer recurrence. However, due to the reversible nature of the DTP cells, investigating the mechanism of this state and developing therapeutic approaches targeting it can facilitate progress in treating drug-resistant cancer and preventing cancer recurrence.

Existing researchers have incrementally developed an initial understanding of DTP cells by integrating observed features. The correlation among these features suggests that DTP cell formation is a holistic and unified process. The characteristics of slow-cell-cycle and reduced proliferation are often expressed in diapause cancer cells.51,88 The static stage and recovery stage of the diapause state of these special cancer cells also demonstrate the rationality of their reversible existence.89–92 Furthermore, the characteristics of the slow-cell-cycle provide a reserve basis for the stemness or plasticity of DTP cells in the multidirectional differentiation preparation stage.93–95

DTP formation as an inert specialization in response to anticancer therapy

After analyzing and summarizing these special features, it is apparent that DTP cells exhibit a complex mechanism of formation characterized by inert specialization in response to therapeutic stimuli. This process involves cell-cycle restriction, diapause, stemness, and reversibility, which are shared characteristics with certain other specialized cancer cells. However, it is important to note that the essence of DTP cells is not entirely consistent with that of other cancer cells.96 The key distinction between DTP and cancer stem cells or dormant cancer cells is their heightened resistance to external drug stimulation. Additionally, their characteristics (Table 1), including origin, phase of existence, proliferative capacity, and tendency for differentiation, vary.Table 1 Related characteristics among DTP cells, cancer stem cells, and dormant tumor cells

	DTP cells	Cancer stem cells	Dormant tumor cells	
Origin	Drug-induced formation	Original mutation unit of cancer cells	Metastatic or residual part transformation	
Exist phase	Anticancer drug treatment period	Early stages of tumor development and differentiation	Early metastasis or Minimal Residual Disease to resist the immune phase	
Proliferation	Low But proliferation restores after the drug withdrawn	High Own ability to unlimited multiply and self-renewal tendency	Extremely Low Hardly proliferate when they are insufficient to counter immunity	
Stemness	Some certain degree of stemness and differentiation exists to response to drug stimulation	High degree of stemness and high differentiation tendency, main significance is tumor heterogeneity	Low degree of stemness and almost exclusively change to ordinary tumor cells	
Stress memory	Possible some degree of memory ability	No relevant memory ability	No memory ability, even no responding to stress	
Resistance	Clearly have resistance	Occasionally have mutagenic resistance	May have limited resistance	
Resistance spectrum	Extensive drug resistance	Mono-drug or multi-drug resistance	Usually manifests as silence in response to stimuli, including drugs	
Resistance mechanisms	Mechanisms of gene mutation and non-genetic regulation	Absence of certain drug sensitive targets resulting from mutations	The self-silence, low metabolism, and survival logic with little interaction	
Markers	Genetic markers: Mex3a,15 APOBEC3304	Stem associated surface antigen markers: CD133,305 ALDH,306 CD90,307 CD44,308 EpCAM309	Dormancy related markers: DEC2/Sharp1,310 p27,311 p21,312 NR2F1313	
Non-genetic specific markers: ALDH,37 PINK-1,38 KDM5A4	

Compared with completely formed drug-resistant cancer cells, DTP cells exhibit characteristics of a slow-cell-cycle and are somewhat inactive; however, they possess little inherent ability of drug-resistant cancer cells to absorb nutrients and persist in proliferating. DTP cells enter a diapause state, leading to the emergence of more generalized and broad-spectrum drug resistance phenomena in terms of drug response, rather than the specific drug resistance reactions seen in drug resistant cancer cells.97 Moreover, there is a notable difference in the reversible nature of drug resistance between the two cell types. The majority of drug-resistant cancer cells undergo genetic changes98 that prevent them from reverting to their original non-resistant state, which contrasts with the potential reversibility observed in DTP cells.

For another type of cancer stem cells that is often mentioned to be similar to DTP, the drug resistance of DTP is a significant feature that cancer stem cells cannot have.99–102 While both types of cells share similarities in terms of stemness, plasticity, and some surface antigen CD molecules,103,104 cancer stem cells primarily function as a reserve subgroup for multidirectional differentiation within cancer cells.105,106 DTP is more of a resister of cancer cells stimulated by external drugs. And the plastic ability of DTP can be compared to an instinctive survival mechanism.107 Moreover, the extremely high proliferative activity108–110 of cancer stem cells contrasts with the slow-cell-cycle of DTP cells,105 underscoring their distinct natures. In this sense, many of what were once called cancer stem cells can be defined as DTP cells that live for survival rather than stem cells that exist for differentiation and proliferation.

After differentiating DTP cells from other types of cancer cells with similar properties and analyzing their characteristics before and after formation, it becomes evident that DTP formation serves as an inert specialization response to therapy, transitioning from a state of inactivity to activity following the conclusion of therapeutic stimulation. This phenomenon poses challenges in fully elucidating the mechanisms behind cancer recurrence and drug resistance, as research neglects the subtle changes in cancer cells during drug treatment. This knowledge gap may underlie the persistent difficulties encountered in addressing drug resistance in cancer. However, by enhancing the understanding of DTP, it becomes conceivable to overcome the obstacles hindering the effective treatment of drug resistance in cancer.

The observed memory effects after DTP cells formation

Additionally, DTP cells exhibit a special feature that cannot be generalized to biological characteristics, but also makes it different from other special cancer cells: several studies60,70 have revealed a memory effect following the creation and reversible restoration of DTP, implying a potentially significant role in the development of genetic, stable, and irreversible drug resistance. Specifically, DTP cells emerging during anti-EGFR therapy in lung cancer demonstrate a remarkable level of resilience that permits the cells to have a highly stable chance of sustaining a response, enabled by the phosphorylation of insulin receptor substrate 1 (IRS1).111 The phosphorylated state bestows various long-term memories upon the modified DTP cells, allowing them to present heritable components when the relevant drug is reintroduced following a treatment interruption. The preservation of epigenetic changes in DTP cells as a heritable memory upon reverting to a drug-sensitive state creates a pathway for the evolution of drug-resistant entities. The process raises the possibility of increased persistence in cells upon drug rechallenge, consequently escalating the frequency of DTP formation and potentially enhancing rates of drug resistance like EGFR-resistant lung cancer cases. While the ultimate impact on drug resistance evolution about DTP cells requires further investigation, the observed memory phenomenon and the terrible likelihood of DTP cells enrichment warrant continued research and validation.

Being explored DTP: Possible mechanisms underlying DTP cells formation and drug resistance

The fact that the DTP cells are potentially reversible and memorable accentuates their pivotal importance as an exploratory subject for investigators. Understanding the biological traits of the DTP condition may not fully elucidate its capacity to withstand the lethal impact of cancerous cells linked to treatment. Therefore, comprehending how the DTP cells arise mechanistically is crucial for the ultimate goal of reversing the DTP cells for therapeutic purposes. The process of forming the DTP cells remains incompletely understood and can vary between cancer cells of distinct cancer, making the study of this process more challenging. Consequently, the mechanisms of DTP cells’ formation are both specific112 and universal,13 highlighting the complex nature of this phenomenon.

The mechanism of DTP formation involves important considerations that need to be examined: i) At a vertical level, there are distinctive characteristics of DTP cells that make them easily distinguishable from pre-forming parental cancer cells and post-resuscitation filial cancer cells and have unique advantages in responding to treatment and demonstrating drug sensitivity.113 ii) At a horizontal level, there are prevalent parallel features that are common to various cancer DTP cells, indicating a commonality across the DTP transformation process of different cancer types.16,61 Consideration of the mechanism of state formation in conjunction with these two aspects will result in a more generalizable and reliable understanding.

This review synthesizes the findings of prior long-term and continuous investigations, outlining the primary mechanisms that give rise to DTP cells (Fig. 4): molecular modification regulation, signaling pathways and transcription regulation, tumor micro-environmental transformation regulation, metabolic shifts regulation, and redox regulation (which is often overlooked but holds significant importance). These mechanisms do not exist in isolation and are not operating under either/or single mechanism conditions.114–117 In most cases, multiple mechanisms work together when cancer cells enter DTP, with one mechanism augmenting another,118,119 rendering DTP cells resistance persistent and challenging to treat and eliminate. In the ensuing segment, we will analyze each mechanism’s traits and interactions point by point.Fig. 4 Multi-mechanisms analysis of DTP resistance. Molecular Modification (a): DTP cells exhibit a significant number of molecular modifications as compared to parental tumor cells, encompassing DNA methylation, acetylation, phosphorylation, and histone modification. Signaling Pathways (b): Signaling plays a crucial role in cancer cells, and altered pathways in DTP cells contribute to transcription regulation, DTP formation, and drug resistance progress. Tumor Micro-environment (c): TME surrounding the DTP cells changes to accommodate both drug action and the environment’s alterations. Metabolic Reprogramming (d): DTP cells rely more on mitochondrial respiration than most cancer cells that survive using glycolysis, for their energy needs. Redox Balance (e): The robust redox system within DTP cells enables them to withstand the balance between oxidative eustress and distress. These multi-mechanisms interact with each other and together provide the stable basis for drug resistance in DTP cells. (Drawn by figdraw)

Regulation of molecular modification and epigenetic reprogramming

The frequent occurrence of molecular modification in cancer involves alterations in DNA or RNA promoter regions, histone acetylation, methylation, or variations in repetitive element expression.120,121 Cancer cells exploit these epigenetic modifications to induce their heterogeneity and develop drug resistance.122–126 Consequently, DTP entities can likely employ analogous non-genetic molecular modifications to initiate epigenetic reprogramming, thereby leading to the emergence of their drug resistance. This shared mechanism is anticipated to play a significant role in drug resistance.

Sharma et al.32 found that the epigenetic regulator histone H3K4 demethylase KDM5A is activated during the formation of the DTP cells in EGFR mutant lung cancer cells. Concurrently, Buenrostro et al.127 also documented epigenetic reprogramming resulting from such molecular modifications. Additionally, the activation of KDM5A was shown to be crucial in inhibiting cell-cycle progression.128–130 A well-established review131 highlights the significant involvement of KDM5A in oncology, closely associating it with cancer growth, differentiation, drug resistance, invasion, and metastasis. Criscione et al.‘s61 study investigated the use of Osimertinib for the treatment of NSCLC and its role in inducing the generation of DTP cells. The study revealed that the DTP cells displayed a distinct gene expression profile compared to the cancer cells eliminated by direct Osimertinib treatment. Specifically, the DTP cells exhibited up-regulation of YAP1 and TEAD genes, and increased susceptibility to inhibition of BRD4, AURKB, and TEAD targets. Moreover, the study found that the expression of MEK-activated genes, including MAPK13, EPCAM,132 ETV4,133 DUSP4,134,135 and PHLDA1,136–138 was down-regulated in the DTP cells. Conversely, MEK compensatory resistance genes, such as IGFBP3,139,140 MAP2,141 and SERPINE1,142 were upregulated and contributed to resistance to anticancer therapy with EGFR TKI in the DTP cells.143 Noronha et al.144 observed the up-regulation of Growth Arrest-specific Protein 6 (GAS6) in residual cells of anti-EGFR treated lung cancer, leading to the subsequent formation of DTP cells. They also found a significant association between the expression of AXL, the receptor for GAS6, and the formation of the DTP cells and drug resistance. Moreover, overexpression of AXL has been demonstrated to enhance DTP cells’ activity and promote the emergence of the common EGFR mutation T790M in drug resistant lung cancer.145–147 The mechanism underlying this effect may involve AXL-induced activation of low-fidelity DNA polymerase and RAD18 through neddylation promotion. Additionally, AXL activation of MYC may lead to an increase in purine synthesis due to pyrimidine imbalance,148 further contributing to drug resistance.148,149 Additionally, a detailed analysis150 of receptor tyrosine kinase (RTK) activation using phosphorylated RTK arrays indicated that exposure of HCC4006 cells to erlotinib leads to the induction of the DTP cells, activating HER family and MET151,152 targets. Based on the previous statements, it is clear that epigenetic reprogramming through molecular modification plays a crucial role in the development of DTP cells and the subsequent emergence of drug resistance.

Regulation of signaling pathways and transcription

Cancer cells are characterized by the presence of numerous specific signaling pathways and dysregulated transcription factors that play a critical role in driving their abnormal proliferation and growth.153–155 Key therapeutic approaches involve the use of targeted drugs aimed at these specific signaling pathways, which have been identified as crucial targets in anticancer therapy.156,157 Notably, the EGFR signaling pathway and its downstream JAK/STAT,158 PI3K/AKT,159,160, and MAPK161,162 signaling pathways163 are among the main targets identified. These pathways play multiple roles in tumor development and have been implicated in drug resistance mechanisms in certain cancer cells.164–167 Additionally, the regulation of molecular modification, previously discussed, directly impacts these signaling pathways and transcription. Therefore, researchers are investigating the potential mechanistic link between signaling pathways and transcriptional changes in the DTP cells by scrutinizing and comparing the signaling pathways and transcription factors of typical cancer cells with those of DTP cells, thereby elucidating the differences between the two.

The molecular modification of the DTP cells involves several key mechanisms: Firstly, the upregulation of AXL expression can be induced by anti-EGFR treatment, which disables the negative feedback loop of SPRY4.168 Consequently, this activation inhibits the cancer cell-cycle through the signaling pathway axis via AXL and its ligand GAS6.169 Secondly, the upregulation of the YAP and TEAD genes is related to the action of the Hippo pathway.61,170 YAP, TEAD, and their complexes function as transcription factors that contribute to the formation of the DTP cells and impact drug sensitivity.156,170 Furthermore, studies171 have indicated that YAP/TEAD may influence the EMT-associated transcription factor SLUG172,173 and impede the apoptosis of cancer cells caused by therapeutic drugs. These examples illustrate how molecular modifications affect the signaling pathway shift, playing a significant role in the formation of the DTP cells.

After treatment with the BRAF inhibitor Vemurafenib in the BRAF (V600E) melanoma model, residual cancer cells have been observed to exhibit compensatory up-regulation of EGFR targets and other pathways associated with overcoming therapeutic drug-induced inhibition of the MAPK pathway.174 It is noteworthy that targeting multiple sites along the EGFR signaling pathway and its downstream pathways, through the combined use of a BRAF inhibitor and an EGFR inhibitor, has shown greater efficacy in treating drug-resistant BRAF (V600E) colon cancer patients.175,176 This observation suggests that alterations in signaling pathways, especially those related to cell proliferation, may have a compensatory effect and participate in the emergence of the DTP cells and the mechanisms that confer drug resistance.

The Wnt/β-catenin signaling pathway is a widely studied association with DTP cells. According to Nie et al.,177 transcriptomics results suggest that YAP can mediate the metabolism of Ach by increasing the expression of the biosynthesis-limiting enzyme choline acetyltransferase ChAT in response to EGFR TKI. This results in the specific accumulation of Ach in DTP cells, ultimately activating the Wnt/β-catenin pathway through Ach Muscarinic Receptor 3 (M3R)178,179 and stimulating β-catenin signaling through the Notch3 pathway.180 Notably, the mutant aberrant activation of the Wnt pathway is a major factor driving most types of tissue stem cells, contributing to the development181 of the DTP cells and the stemness182–184 of DTP cells.

The formation of the DTP cells involves the identification of several other signaling pathways. Osimertinib treatment has been found to upregulate the Notch pathway in DTP cells,185 and this pathway significantly interacts with the EGFR pathway. Moreover, the IGF-1R pathway and its associated Akt pathway, linked to KDM5A and H3K4 targets, are also modulated in DTP cells.186 Additionally, the activation of the transcription factor FOXA1 has been observed in EGFR mutant NSCLC treated with Osimertinib, resulting in the upregulated expression of IGF-1R and induction of the DTP cells.187

The association between certain pathway changes and resistance to DTP cells is established, while others are still under investigation. Nevertheless, numerous signaling pathways are undoubtedly altered during the formation of the DTP cells (Fig. 5).Fig. 5 As shown above, DTP cells undergo numerous modifications to genes and signaling pathways. Important modifications include KDM5A-mediated DNA methylation modification, increased expression of GAS6/AXL, adjustments to EGFR, JAK/STAT3 and their downstream pathway, activation of the Hippo pathway and its YAP/TEAD branch, the Notch pathway, the Wnt/β-catenin pathway, and modulation of E-cadherin. Ultimately, the drug resistance of DTP cells has been affected. (Drawn by figdraw)

Regulation of tumor micro-environmental transformation

The tumor micro-environment, located at the site of the tumor, comprises non-cancerous cells such as stroma and immune cells, and it plays a crucial role in tumorigenesis, progression, metastasis, and treatment response.188–190 Influenced by tumor factors, this micro-environment can lead to drug resistance in several ways.191–193 During the transition of cancer cells to DTP cells, the composition and contents of the micro-environment undergo a transformation as cancer cells and cancer associated fibroblasts (CAFs)194–196 directly or indirectly influence it, to adapt to the corresponding changes and demands.

The micro-environmental transformation includes epithelial-mesenchymal transition (EMT), epithelial cell development, vesicle-mediated transport, drug metabolism, and cholesterol homeostasis.42 Studies have indicated the association of this transformation with molecular modifications197,198 and alterations in signaling pathways199,200 during the development of the DTP cells. Furthermore, changes in the micro-environment were evident in environments associated with extracellular matrix (ECM) secretion, EMT, the TGF-β/SMAD signaling pathway, and other processes.61 Also noted is a micro-environmental state of high mesenchymal state.201 The modification of the mesenchymal state, induced by the EMT regulator with the lipogenic factor ZEB1,202,203 leads to an elevation in enzymes responsible for polyunsaturated fatty acid synthesis. This increase in enzyme activity results in a deficiency of substrates for lipid peroxidation by lipoxygenase, subsequently reducing the presence of lipid peroxides and lowering the risk associated with drug therapy. Therefore, the transformation in treatment is critically linked to the altered mesenchymal state driven by the EMT regulator and ZEB1, which effectively modifies the cellular environment to mitigate lipid peroxidation and the drug’s efficient effects.

The crucial role of the micro-environment associated with DTP in forming drug resistance has been highlighted by a study conducted by Suda et al. 150. In this study, a TGF-β-mimicking EMT state204 was utilized to culture HCC4006 cells, resulting in the generation of erlotinib-resistant DTP cells, denoted as HCC4006ER. The findings of the study revealed that the TGF-β cultured cells exhibited resistance to erlotinib, similar to the erlotinib-resistant DTP cells. The subsequent analysis150 through immunoblotting revealed that both HCC4006ER and DTP cells showed SMAD2 phosphorylation205 and down-regulation of E-calmodulin.206 Moreover, it was observed that erlotinib sensitivity in HCC4006 cells, which were cultured with TGF-β, was restored upon withdrawal of TGF-β. The formation of DTP cells and the associated changes to the tumor micro-environment raise questions about their causal relationship. It is uncertain whether DTP cells initiate changes to the tumor micro-environment or if the micro-environmental transformation precedes the development of DTP cells. While DTP cells may not directly instigate changes in the tumor micro-environment, the tumor micro-environment plays a crucial role in DTP formation and its acquisition of drug resistance. Therefore, attributing them to the mechanism of DTP formation is a justifiable approach.

Regulation of metabolic reprogramming

The alteration of energy metabolism stands out as a hallmark of cancer cells, characterized by a key marker named the Warburg effect.207 According to current knowledge, cancer cells favor the utilization of anaerobic glycolysis as their primary pathway for energy acquisition,208,209 involving the conversion of glucose to pyruvate and subsequently to lactate. On the other hand, DTP cells display a preference for utilizing mitochondrial respiration and the electron transport chain to acquire energy.32 This distinction in energy acquisition pathways underscores the metabolic differences between cancer cells and those DTP cells, indicating the potential for targeted therapeutic strategies based on metabolic alterations in cancer cells. Raha et al.41 proposed that elevated ALDH levels may be indicative of cancer cell conversion into DTP cells. To investigate this claim, the researchers conducted a study comparing homozygous cancer cells with different levels of ALDH expression. They measured the oxygen consumption rate (OCR), an indicator of mitochondrial electron transport chain (ETC) activity. Their findings revealed that cells with high ALDH expression displayed an increased basal OCR, along with elevated mitochondrial respiration and ROS production. Subsequent analysis and other research210 demonstrated that cells exhibiting high OCR and increased ROS production were capable of expressing higher levels of ALDH1A1. This suggests that DTP cells may rely on oxygen and mitochondria for survival.

Currently, the reliance on mitochondrial respiration has been demonstrated in drug-resistant cancer cells and DTP cells from multiple cancer sources.211–215 In BRAF-mutated melanomas, blocking the mitochondrial respiratory chain of slow-cell-cycle JARID1B(high) cells, now referred to as DTP cells, has been proven effective in inhibiting their drug resistant behavior.78 Furthermore, in the field of triple-negative breast cancer treatment research,49 Phase 1 clinical development is underway to investigate the efficacy of an oxidative phosphorylation inhibitor. Researchers have reported that this inhibitor49 can target cancer cells in a reversible drug-resistant state and hinder the effects of residual tumor regeneration, indicating its potential as a promising treatment strategy.

The development of DTP cells is partly characterized by a metabolic shift, leading to an increased reliance on oxidative phosphorylation for energy, as observed in the above studies.41,49 Consequently, there is a concurrent rise in ROS levels within the cells. This elevation in ROS triggers a natural mechanism of redox regulation, which serves to counteract not only ROS but also other metabolites in the cellular environment.

Regulation of integrated complex redox systems

Cells have developed intricate detoxification mechanisms, including the production of molecules with strong reducing properties, such as cysteine and glutathione, in response to the accumulation of toxic by-products caused by the production of oxidative metabolites in cellular metabolism and other cellular activities.216,217 The detoxification mechanisms also involve the elimination of toxic oxidative metabolites, including peroxides and lipid peroxides,218–220 that can cause cellular damage. This signifies the adaptive response of cells in mitigating the potential harm caused by the accumulation of these toxic by-products.

Cancer cells, although they are a less harmonious part of the organism, are subject to the same basic redox rules.221,222 These cells have their redox mechanisms to protect themselves from the oxidative by-products of their metabolism.223 However, the protective capacity of these mechanisms is limited, and external factors such as antineoplastic drugs disrupt the balance224 between the redox protection mechanisms maintained by normal cancer cells and the oxidatively-derived damage caused by external factors.225–227 As a result of this disruption, normal cancer cells become damaged and transformed (Fig. 6). To address the redox imbalance that occurs when cancer cells transition to the DTP cells, it is important to adjust and reconstruct the redox regulatory mechanisms and effectively respond to the negative effects of drug therapy.Fig. 6 Redox regulation in DTP cells. The Redox System Balance (a/b) is influenced by mitochondrial respiratory metabolism, anticancer therapeutic drug effects, radiotherapy, inflammatory stimulation, and external oxidative stress. These factors elevate the ROS level of DTP cells (Pro-Oxidation Part). Then DTP meets these oxidative stimuli by multiple reductive protection mechanisms with redox compensation like GSH/NADPH/HK2 through enhancing the expression of GPX4 and ALDH, and other potential related elements (Pro-Reduction Part). The balance between the two ensures the redox stability of DTP cells. Other potential redox mechanism (c): external drug stimuli, particularly BH3-mimetics can trigger an incomplete mitochondrial outer membrane permeabilization (iMOMP) in DTP cells by acting on Bcl-2 family anti-apoptotic proteins (including BAX, BAK, BOK, etc.) and reducing caspase activation. Drug treatment protects DTP cells from apoptosis by inhibiting membrane permeabilization and caspase activation. Additionally, a protective mechanism against oxidative stress in DTP is stimulated by the drug, which acts on the cytochromeC-HRI-eIF2a-ISR/ATF4 axis. (Drawn by figdraw)

Reactive oxygen species (ROS) are indispensable for maintaining the normal redox system.228,229 By inducing oxidative stress in cells, ROS can disrupt the cell’s antioxidant system established for homeostasis, ultimately leading to cell death. Notably, cancer cells are not immune to the effects of ROS, and some drugs harness this phenomenon to selectively eliminate cancer cells for therapeutic purposes. The formation of DTP cells not only showcases redox-regulated mechanisms but also reveals their resistance to pro-ROS drugs. This resistance is supported by the metabolic changes mentioned earlier, in addition to the enhanced mitochondrial functioning of DTP cells, which involves their ability to acquire energy through oxidative phosphorylation and other mechanisms associated with elevated levels of ROS.230 Zhang et al.33 discovered a higher concentration of GPX4 and ferrous ions in DTP cells obtained from a colorectal cancer model treated with 5-FU. GPX4, also known as glutathione peroxidase 4, can utilize GSH to directly reduce phospholipid peroxide, thereby protecting cells from oxidative stress induced by chemotherapy.231–233 Other studies234,235 have also reported the protective role of GPX4 in DTP cells against oxidative stress. Furthermore, ferrous ions, as a component of iron transport, play a role in the redox mechanism, which aligns with the association between total iron content, labile iron pool (LIP), and high CD44 expression57 in DTP cells. These findings suggest that the transport of iron involved in the redox mechanism may contribute to drug resistance. Subsequent studies involved the knockout of the GPX4-related gene in DTP cells, which revealed that GPX4 KO led to significant sensitivity to lipid peroxidation in the primary and mild sensitivity to ordinary oxidative stress in the secondary. Moreover, GPX4 KO DTP cells exhibited oxidative stress damage that could not be rescued by the antioxidants Ebselen and EUK134 but could be rescued by the lipophilic antioxidant ferrostatin-1.8 Collectively, these findings point to the reliance of DTP cells on GPX4.32,41 Loss of GPX4 function in vitro resulted in selective DTP cells death due to iron, suggesting the potential to prevent cancer recurrence.236,237 Furthermore, a comparison between DTP cells and their parental common cancer cells revealed that DTP cells display heightened sensitivity to GPX4 inhibition, increased levels of lipid ROS, elevated expression of reduced GSH-specific γ-glutamyl transferase 1 (CHAC1), and reduced expression of glutamate-cysteine ligase catalytic subunit (GCLC), indicating the necessity of GPX4 for DTP cells.238 Furthermore, in the maintenance of the DTP cells, the expression of ALDH (aldehyde dehydrogenase) is considered essential. Cancer cells with high ALDH expression have been found to exhibit greater resistance than those with low expression. Raha et al.41 conducted a study on the gene expression changes in DTP cells derived from the MET-induced gastric cancer cell line MKN-45, before and after treatment with the MET kinase inhibitor Crizotinib. The study revealed that the drug-resistant subpopulation exhibited increased ALDH1A1 expression. Although multiple ALDH isozymes exist, ALDH1A1 is particularly significant. However, the researchers found that knocking down ALDH1A1 alone did not hinder DTP formation. Instead, they observed increased expression of other ALDH isozymes, indicating potential redundancy within the ALDH family in response to drug-induced upregulation. ALDH is involved in the redox mechanism and facilitates the formation of DTP cells. Its related proteins play a role in catalyzing the oxidation of metabolically produced aldehydes, thereby controlling their cell-damaging effects. This scavenging activity may contribute to DTP formation as these enzymes can detoxify cancer cells from toxic aldehydes produced by certain chemotherapeutic drugs,239 contingent upon the cellular redox state. Additionally, the presence of ALDH may protect cells against the toxic potential of ROS.240,241 Disrupting ALDH activity with drugs could result in the accumulation of toxic levels of ROS, leading to DNA damage and apoptosis in a subset of DTP cells.41 Kalkavan et al.238 discussed a study involving sublethal mitochondrial outer membrane permeabilization (MOMP) and the cytochrome C related redox regulated transformation of DTP cells. The research started with an investigation of commonly used drugs that target the apoptosis-intrinsic pathway for treating DTP cells. It was found that BH3-mimetics, designed to act on Bcl-2 family effector proteins (specifically BAX, BAK, and BOK, which are responsible for mitochondrial outer membrane permeabilization MOMP-induced apoptosis242,243), have a BH3-like impact on apoptosis induced cell death. The binding of BH3-only proteins to anti-apoptotic proteins, either via their BH3 domains or by directly binding with BAX and BAK to form MOMP, results in incomplete mitochondrial outer membrane permeabilization (iMOMP).244 This iMOMP event induces minimal caspase activation, which in turn promotes the protection of cell survival and contributes to the formation of DTP cells.245,246 In addition, therapeutic agents induce upstream stress that affects the cytochrome C in the cytoplasm of cancer cells, leading to the activation of the heme-regulated inhibitor EIF2AK1 kinase (HRI, which also contains EIF2AK2/PKR, EIF2AK3/PERK, EIF2AK4/GCN2). This activation leads to the phosphorylation of the translation initiation factor eIF2a, resulting in translational reprogramming and the inhibition of global cap-dependent translation. Thereafter, it participates in the integrative stress response (ISR) and activates the transcription factor ATF4, which initiates the corresponding gene expression program. This process ultimately increases nutrient uptake and autophagy in the short term, suppressing oxidative stress to promote survival.247,248

Considering these redox regulated adaptive changes, it is evident that the fundamental link between the DTP cells and cellular homeostasis is facilitated. These regulatory systems enable cancer cells to enhance their adaptive capacity when confronted with oxidative stress damage induced by treatment, thereby playing a pivotal role in the formation of DTP.

Linkage and interaction between mechanisms

The close connection between molecular modification, signaling pathway regulation, tumor micro-environment regulation, metabolic transformation, and redox homeostasis synergistically and collectively supports DTP cells in resisting the cytotoxic effects of drugs.

Both molecular modifications and signaling pathways are intertwined in a symbiotic relationship.249 Molecular alterations instigate changes within their corresponding signaling pathways, setting off a chain reaction of adaptations throughout the cellular structure. The consequential cellular transformations and protein responses resulting from these interactions play a significant role in shaping the tumor micro-environment. For instance, the involvement of the type 3 muscarinic acetylcholine receptor (M3R) in signaling pathway regulation is crucial for the phosphorylation of VE-cadherin and β-catenin tyrosine,250 thereby influencing the presence and function of cadherin and other factors that regulate the tumor micro-environment.251 These modifications and adjustments have cascading effects on the metabolic system, leading to shifts in energy requirements and alterations in metabolite outcomes. Furthermore, redox regulation has far-reaching mutual effects beyond its direct impact, influencing molecular modification, signaling pathway regulation, and causing micro-environmental shifts that facilitate the transition of regular cancer cells into a slow-cell-cycle state. Puig et al.252 showcased the role of oxidative stress-regulated TET enzymes in cancer cells, which directly impact DNA methylation, initiating the transition to a slow-cell-cycle state and promoting the formation of DTP cells. This demonstrates the direct influence of redox regulation on molecular modification and the promotion of a slow-cycling state. The critical role of redox regulation, as a key aspect of metabolism, significantly affects various mechanisms involved in the development of DTP cells.

By optimizing the synergistic combination of different mechanisms, it is possible to mitigate the stress damage induced by cancer treatment, transforming normal cancer cells into DTP cells that are better equipped to withstand such stressors, thus improving survival conditions.

Worth recognized DTP: Overview of clinical research progress of anti-DTP therapy

After surviving anticancer therapy, DTP cells exploit their inherent biological properties to develop drug resistance, leading to resistance to subsequent therapy or cancer recurrence following treatment. Addressing these hard-to-treat DTP cells through drug intervention represents a breakthrough in anticancer therapy. To achieve this, understanding the formation mechanism of DTP cells and their resistance-related properties provides a basis for subsequent therapeutic management. Accordingly, exploring solutions to reverse the drug-resistant state of DTP cells, leveraging their reversible nature, emerges as a promising avenue for further research.113

Overview of anti-DTP therapy

As researchers deepen their understanding of DTP cells, focusing on how to target the formation of DTP cells and what aspects of the formation mechanism have naturally been a consistent interest. Up to now, the primary strategies of anti-DTP therapy can be summarized in the following parts: (1) Targeting molecular modification to prevent normal cancer cells from converting to DTP cells; (2) Targeting signaling pathways to inhibit the formation of DTP cells; (3) Targeting the tumor micro-environment, where DTP cells exist, to either weaken environmental drug resistance or enhance their sensitivity; (4) Targeting the cyclic hysteresis of DTP cells formation, waking up dormant cancer cells; (5) Targeting the intrinsic conditioned homeostasis of DTP cells necessary for tolerating environmental stresses. Numerous studies5,8,253 have underscored the significance of various approaches in tackling DTP cells in cancer treatment. Each approach possesses unique features and practical applications, but they also come with limitations. Despite the implementation of solutions to combat DTP cells, current conditions remain unsuitable for fully eradicating them, as indicated by several studies. However, the positive outcomes of these strategies include a reduction in the presence of DTP cells, reversal of initial drug resistance in some tumors, and decreased possibility of cancer recurrence in the long run.23 This highlights the importance of gaining a deeper understanding of these effective drugs in clinical oncology treatment and emphasizes the necessity for further research in this area.77,110

From a clinical perspective, it is essential to consider the overall role of a drug in the human body, which is a complex system, even though studying targeted drugs through their corresponding mechanisms is a suitable direction from a research and exploration standpoint. A narrow focus on the drug’s mechanism of action can lead to over-mechanized thinking and overlook its broader impact. Moreover, solely emphasizing the counter mechanism can lead to blindly pursuing new drug development while overlooking the feasibility and accessibility of medications, thereby neglecting the re-evaluation of other traditional anticancer treatments. This review aims to expand on the subject of anti-DTP treatment to effectively address the above-predisposed bias errors. Specifically, it will examine three different treatment tendencies, namely (a) experimental medicine mode, (b) traditional medicine mode, and (c) traditional Chinese medicine-assisted mode, based on existing traditional treatment, clinical experiments, and Chinese medicine treatment. By considering the scope of current and potential treatment related research, such a classification method review seeks to offer a comprehensive perspective and establish a more robust framework for the selection and implementation of anti-DTP therapy in clinical settings. (Fig. 7, Table 2).Fig. 7 Selected Anti-DTP drugs. a: Preclinical drugs; b: Novel use for old drugs; c: Natural products. (Drawn by chemdraw)

Table 2 Summary of three models covering different classes of drugs for DTP cells in cancer

Drug name	Cancer type	Target mechanism	Target point	Side effect	Ref.	
Drug Type: Preclinical drugs	
RSL3, FIN56	Colorectal cancer	Redox homeostasis	GPX4	Non-clinical trial	33	
MS-275	Lung cancer	Molecular modification

Tumor micro-environment

	HDAC family

E-Cadherin

	Phase 1/2

Acute toxicity

Skin/Eye Irrit.

	150	
AZD2811	Lung cancer	Molecular modification

Signaling pathway

	Aurora B kinase

ATR-CHK1-Aurora B signaling

	Phase 1/2

Unknown toxicity

	17	
GSI	Lung cancer	Signaling pathway	NOTCH signaling	Non-clinical trial	185	
Silvestrol	Glioblastoma & Pancreatic cancer	Signaling pathway Transcription regulation	eIF4A

AKT/mTOR,

ERK1/2 signaling

	Non-clinical trial	314,315	
LGK-974	Breast & Colorectal cancer	Signaling pathway	Wnt/β-catenin signaling	Phase 1/2

Unknown toxicity

	316–318	
ONO-7475	Acute myeloid leukemia & Lung cancer	Molecular modification	AXL	Phase 1/2

Unknown toxicity

	319–321	
BH3-mimetic

(ABT-263, ABT-199)

	Prostate & Rectal cancer

Lymphoma

	Molecular modification

Metabolism conversion

	Bcl-2	Phase 1/2/3

Unknown toxicity

	254	
CPI-455	Lung & Esophageal cancer	Molecular modification

Metabolism conversion

	KDM5

Mitochondrial pathway

	Non-clinical trial	284,322,323	
KS100	Melanoma	Molecular modification

Redox homeostasis

	ALDH family	Non-clinical trial	324	
Drug Type: Novel use for old drugs	
Fluvastatin	Pancreatic cancer	Tumor micro-environment

Redox homeostasis

	HMG-CoA

GPX4

	Hepatotoxicity

Reproductive toxicity

	201,325	
Disulfiram	Thyroid & Lung cancer	Molecular modification

Redox homeostasis

	BMI-1

ALDH family

	Hepatotoxicity

Reproductive toxicity

Skin/Eye/

Respiratory

Irrit.

	266,326,327	
Darifenacin	Lung cancer	Signaling pathway	Ach/M3R signaling	Hepatotoxicity

Anticholinergic effects

	177	
2-DG	Pancreatic cancer	Metabolism conversion	Hexokinase-2	Acute toxicity	328,329	
Chloroquine	Liver & Breast cancer	Metabolism conversion

Signaling pathway

	HGF-MET signaling	Hepatotoxicity

Reproductive toxicity

Group 3 carcinogen

Convulsive seizures

Headache

	330,331	
Drug Type: Natural products	
β-Elemene	Ovarian cancer	Molecular modification

Metabolism conversion

Cycle slowness

	Bcl-2/XL, Bax

Cyclin A, Cdc2

	Acute toxicity	332–334	
Curcumin	Colorectal cancer	Signaling pathway	Notch/Wnt signaling	Acute toxicity	335	
Resveratrol	Colorectal cancer	Molecular modification

Signaling pathway

	Nrf2

NF-κB signaling

	Hepatotoxicity

Reproductive toxicity

	336	
Emodin	Renal cancer	Redox homeostasis	ROS levels

JNK signaling

	Electrolyte-unbalance

Diarrhea

	271	
Celastrol	Ovarian & Colorectal cancer	Molecular modification

Signaling pathway

	SIRT

STAT signaling

	Acute toxicity	337–339	
Crypto-tanshinone	Melanoma & Prostate cancer	Molecular modification

Metabolism conversion

Redox homeostasis

	Bcl-2

ROS-mitochondrial pathway

	Acute toxicity	340,341	
Evodiamine	Non-small-cell lung cancer & Breast cancer	Signaling pathway	NF-κB, Smad2/3

TGF-β/HGF

SOX9-β-catenin signaling

	Acute toxicity	271,342,343	
Salvianolic acid B	Gastric cancer & Colorectal cancer	Signaling pathway

Tumor micro-environment

Redox homeostasis

	AKT/mTOR signaling

ROS levels

EMT suppression

	Unknown toxicity	344–346	
2-DG 2-Deoxy-D-glucose, GPX4 glutathione peroxidase 4, HDAC histone deacetylase, NOTCH translocation-associated Notch protein, eIF4a eukaryotic translation initiation factor 4A, AKT protein kinase B, mTOR mechanistic target of rapamycin kinase, ERK extracellular regulated protein kinase, WNT wingless-type MMTV integration site family, AXL AXL receptor tyrosine kinase, BCL B cell lymphoma protein, KDM5 lysine demethylase 5, HMG-CoA 3-hydroxy-3-methyl glutaryl coenzyme A reductase, BMI-1 B-cell-specific Moloney murine leukemia virus insertion site 1, HGF Hepatocyte growth factor, Cdc cell division cycle, NRF2 NF-E2-related factor 2, NF-κB nuclear factor kappa-B, JNK c-Jun N-terminal kinase, SIRT Sirtuins protein, STAT Signal transducers and activators of transcription, Smad drosophila mothers against decapentaplegic protein, TGF-β transforming growth factor-β

Anti-DTP drugs in experimental medicine mode

Participating in clinical trials is often a viable option for patients with relapsed or resistant refractory cancer, warranting the attention of both healthcare providers and patients. The core of this experimental medicine model lies in preclinical drugs, which work by elucidating newly discovered mechanisms and developing new drugs to tackle challenging issues. Among the primary categories of preclinical drugs are those undergoing validation processes or based on theoretical principles to combat drug tolerance and resistance in cancer. An exemplar in this category is the BH3-mimetics,254 known for generating numerous Bcl-2 inhibitors and serving as an anti-DTP agent that obstructs molecular modification and metabolic aspects of DTP cells.255–258 The widely researched drug ABT-263259,260 falls within this group. While displaying potential in inhibiting resistance in DTP cells, this anti-DTP model is hindered by a critical limitation: the lack of clinical application experience, leading to uncertainties regarding its efficacy, potential side effects, and harm to humans, as illustrated by ABT-263. Despite the initiation of clinical trials across various programs and the endorsement of numerous phase 2 and 3 trials,261–265 the presence of side effects or toxicity remains indeterminate, necessitating prolonged drug usage and further pertinent data. Furthermore, the adherence of cancer patients opting for clinical trials is often disparate, with a significant number unable to complete the trial, due to the lack of patience and courage. Nevertheless, this segment of preclinical drugs holds the highest potential for advancing treatment research and developing more precise anticancer resistance therapy.

Anti-DTP drugs in traditional medicine mode

In today’s anticancer therapy landscape, traditional anticancer approaches still hold significant importance. However, the issue of drug-resistant cancer has previously cast doubts on the effectiveness of conventional therapy. This skepticism stemmed from a historical oversight regarding the reversible nature and partial memory capacity of DTP cells. Researchers, in the past, lacked confidence in traditional treatments due to the prolonged dormancy of drug-stimulated cancer cells in DTP, neglecting the possibility of their reactivation and vulnerability to the original drugs during the recovery phase, potentially leading to the destruction of transitional DTP cells. Therefore, it is not surprising that novel use for old drugs is being proposed. This new approach aims to redirect attention to drugs, whether with known anticancer properties or not, to investigate their relevance in combating DTP cells and to provide guidance on their usage in this context. Past extensive exploration into the properties, contraindications, and side effects of these drugs has been conducted, leading to their widespread adoption in treatments. For instance, disulfiram has exhibited efficacy in aiding cancer-resistant therapy by preserving redox homeostasis.266 Nonetheless, a notable challenge lies in the lack of clear dosages for many drugs selected for anti-DTP therapy, as effective doses often approaching toxic levels. Addressing these dosing uncertainties would require further extensive research—a daunting task that lies ahead. However, it is a piece of great news that expanding the application of this concept beyond oncology-focused drugs and conducting comprehensive screenings for potential anti-DTP therapy could pave the way for the future development of innovative treatment strategies.

Anti-DTP drugs in Traditional Chinese Medicine assisted mode

The empirical cases of Traditional Chinese Medicine (TCM) contributing to the diagnosis and treatment of tumors indicate that traditional Chinese medicine plays a significant role in anticancer therapy,267–269 which cannot be overlooked.270 The emphasis on natural products in traditional Chinese medicine can aid in promoting the concept of anticancer treatment, appealing to cancer patients who opt for traditional Chinese medicine due to their preference for natural remedies over synthetic drugs. Natural products, primarily derived from natural bacteria and Chinese herbs, consist of antifungal and related components that offer diverse and intricate effects. While these natural products exhibit multifaceted drug efficacy, their precise influence on cancer cells and quantifiable impacts remain challenging to analyze. Nevertheless, notable examples, such as emodin’s ability to modulate reactive oxygen levels and disrupt the redox system equilibrium in cancer cells, highlight promising avenues for research.271 Despite the potential benefits, the inherent trace toxicity of many natural products complicates their application, necessitating strategies for mitigating adverse effects. Although the understanding of natural products remains limited, the vast array of components provided by nature offers abundant opportunities for exploration and discovery. Therefore, a comprehensive investigation of natural products represents a parallel approach to advancing anticancer treatment within the realm of traditional Chinese medicine.

Overall, it is hoped that such a categorization will provide methods and inspiration for the clinical management of DTP cells.

Anticipated DTP: Challenges and prospects of anti-DTP therapy

The previous section provided a brief overview of the components involved in anti-DTP therapy. In the following section, we will delve deeper into the fundamental aspects of anti-DTP therapy and analyze its future directions and perspectives. The primary aim of anti-DTP therapy is to administer the treatment as necessary and feasible, while carefully weighing its benefits and risks, and being well-prepared to manage drug interactions, dosing regimens, and side effects.

The necessary for anti-DTP therapy

When considering the necessity of treatments, it is essential to account for the ethical implications. In scientific research, emphasis is placed on cells, animals, and organ-like models, while clinical medicine prioritizes the treatment of patients. Thus, the significance of anti-DTP treatment in cell and animal experiments might differ from its application in cancer patients. In basic research, researchers can assert the necessity and meaning of anti-DTP treatment. However, in medical treatment, the acceptance of a medical intervention should not hinge on the question of necessity.

This is particularly pertinent in oncology where repetitive questioning of the necessity of treatments is trivial. Historically, surgical methods for tumors did not entail postoperative adjuvant chemotherapy or neoadjuvant therapy. Yet, presently, nearly all surgical interventions for solid tumors, particularly intermediate- and advanced-stage malignant tumors, stress the essentiality of postoperative adjuvant chemotherapy. This is because clinical evidence has demonstrated the efficacy of postoperative adjuvant chemotherapy in enhancing the outcomes of such tumors. It has been shown to improve the 5-year survival rate,272,273 as well as reduce the likelihood of cancer recurrence and metastasis274 following surgical treatment for these tumors.

Despite the lack of extensive clinical data on anti-DTP therapy, insights from in vitro experiments and organoid models suggest its potential to inhibit the development of drug resistance in cancer cells. Although one study by Yi Pu et al.4 mathematically supports the ability of anti-DTP therapy to lessen drug resistance, it is imperative to acknowledge that it is purely theoretical and requires validation through further clinical studies. Drawing from the mathematical analysis, it can be inferred that administering anti-DTP therapy after initial anticancer treatment can effectively alleviate drug resistance and tumor burden in the long term, making it an indispensable aspect of comprehensive anticancer therapy. The encouraging news is that an increasing number of relevant therapeutic studies are being conducted. For instance, Navitoclax,265 a clinical drug developed based on ABT-263, has shown promising results in combating drug resistance in DTP cells associated with drug-resistant lymphoma,275 EGFR-resistant NSCLC,276, and recurrent epithelial ovarian cancer.277 This serves as sufficient evidence to demonstrate the effectiveness of anti-DTP therapy in treating drug-resistant tumors. However, due to the limited availability of existing clinical trial data, widespread acceptance of anti-DTP therapy remains challenging. Therefore, further comprehensive research on anti-DTP therapy will be the focal point of the next era in addressing cancer resistance.

Furthermore, in the context of targeted therapy for NSCLC, many patients have had to undergo multiple rounds of changing targeted drugs due to the inadequacy of existing FDA-approved drugs in addressing multi-drug resistance.278 In the face of this challenge, anti-DTP therapy may be recognized as crucial in reducing the emergence of such drug resistance, thereby becoming a necessary intervention. It is hoped that the future availability of more extensive clinical data will be instrumental in establishing this necessity as a standard guideline.

The feasibility for anti-DTP therapy

The feasibility of anti-DTP therapy is a significant concern given the current limitations in drug development. Even though previous research has identified several potential anti-DTP drug components, many of them are still in the preclinical stage, raising uncertainty about their effectiveness in the complex human body environment.279 While these components have exhibited the ability to inhibit DTP formation in vitro and target DTP cells for destruction,41 their efficacy in vivo is still uncertain due to potential challenges related to metabolic distribution and kinetic action. It is essential to maintain a balanced and objective approach when discussing the potential side effects and toxicity of anti-DTP drugs.

Despite these limitations, current evidence suggests that anti-DTP therapy may be a feasible and necessary approach for anticancer treatment.33 Currently, utilizing low toxicity or harmless novel use for old drugs and natural products280 represents a promising direction, even though they may not directly target the DTP cells. Nonetheless, their multifaceted effects can still have a significant impact and may be preferable for reducing side effects when used in integrative treatment.281

In addition, the treatment of SCLC could be evidence, which involves targeted therapy with Niraparib282 after chemotherapy to reduce the tumor burden caused by the expansion of cancer cells that were not killed by chemotherapy.283 In the past, the understanding of MRD was more focused on targeting common cancer cells that were not completely removed. However, when combined with the existing analysis of DTP cells, it is possible that these surviving cancer cells have undergone non-genetic changes and now exist as DTP cells. It is important to consider this possibility when developing treatment plans. The long-term targeted therapy indirectly kills the repopulating ordinary cancer cells that have converted back from DTP cells. This indirect action has been proven to have therapeutic significance. Therefore, anti-DTP therapy that directly acts on DTP cells should be considered (Fig. 8). What’s more, the indirect long-term regimen of targeting ordinary cancer cells formed by DTP presents a hidden danger in terms of longer-term efficacy. This is due to the possibility of developing drug resistance when DTP is transformed into repopulating cells, which increases the risk of recurrence.113 Direct targeting of the DTP cells is necessary to ensure a lower risk of recurrence, emphasizing the need for anti-DTP therapy.Fig. 8 Anticancer Therapy Long-Term View. Past known axis (a) focuses on the drug resistance progress of minimal residual disease (MRD) after anticancer therapy and pursues to prevent the generation of MRD which leads to cancer recurrence. However, the emergence of a new possible axis (b) acknowledges the presence of DTP cells and reactivated one as the fundamental condition. Consequently, two new therapeutic schemes are proposed to simultaneously inhibit and eliminate DTP, thereby aiming for better long-term therapeutic results. (Drawn by figdraw)

Furthermore, understanding and familiarity with the drug resistance mechanisms related to the DTP also provide meaningful support for the feasibility of anti-DTP therapy. These mechanisms are interconnected and complementary, allowing one to compensate for each other and maintain DTP cells’ homeostasis. However, this interconnectedness also renders the system vulnerable to targeted attacks that can disrupt the balance and lead to system collapse. Researchers have identified various potentially targeted basic mechanisms of DTP, such as molecular modifications like KDM5A284 and GAS6,285,286 regulation of pathways including Hippo61 and Wnt/β-catenin,177 and maintenance of redox homeostasis by components like GPX433 and ALDH.287 Several in vitro studies targeting these mechanisms have yielded promising results,238,288 such as anti-DTP therapy targeting GPX4 has shown reductions in drug-resistant cancer cells,8 and inhibition of the mTOR pathway reversed DTP cells formation.80 Understanding the molecular modifications, signaling pathway regulations, and redox homeostasis underlying DTP cells suggests the feasibility of advancing from in vitro trials to clinical trials for validating anti-DTP therapy validation. Nonetheless, challenges remain, particularly in targeting resistance components in DTP cells while minimizing impacts on normal tissues. Despite these obstacles, the promise of anti-DTP therapy in cancer treatment underscores the importance of pursuing its development without delay.

Utilization and prospects of anti-DTP therapy

As previously mentioned, anti-DTP therapy is significant. Therefore, its use is noteworthy. Similar to previous comprehensive oncology regimens, the potential benefits of anti-DTP therapy can be considered based on timing. The following outlooks can be initially considered: 1. Anticancer therapy combined with anti-DTP therapy: 1a) during the treatment period, or 1b) during the inter-therapeutic period; 2. Anticancer therapy followed by anti-DTP therapy: 2a) lethal or 2b) inhibitory.

The strategy of combining anti-DTP with anticancer therapy could be considered a promising approach. Direct combination of anti-DTP drugs during the therapeutic period offers the advantage of fusing anticancer and anti-DTP drugs. This approach can potentially enhance the efficacy of anti-DTP therapy without extending the patient’s hospitalization period, thereby ensuring improved quality of life and compliance. Compound Match Formulations,289 as a newer dosing regimen, are a good way forward for this treatment. Nonetheless, the potential drawbacks include unresolved concerns about drug interactions between existing antineoplastic drugs and anti-DTP, as well as the hepatic and renal loads resulting from the combined metabolism of the two drugs. Conversely, the inter-treatment period approach is viewed as more feasible for reducing the drug load and preventing delayed DTP formation. However, the potential impact of additional anti-DTP treatment on the patient’s body, such as the risk of infections, needs further investigation. Furthermore, the patient’s acceptance of the potentially more complex treatment regimen is another crucial aspect to be addressed. In summary, the role of an additional anti-DTP treatment with anticancer therapy provides a more considered approach to preventing DTP formation.

Another perspective on anti-DTP therapy involves transforming long-term maintenance therapy following existing anticancer combination therapy. This transformation shifts the focus from targeting expanded MRDs to targeting their potential origin – DTP cells. Additionally, anti-DTP therapy offers various options due to the different mechanisms of action of the drugs. For instance, inhibitors targeting GPX4 can directly eliminate DTP cells, while drugs like Fluvastatin act in the tumor micro-environment to primarily inhibit DTP transformation.8 Consequently, the addition of anti-DTP therapy after anticancer therapy can involve regular killing of DTP, continuous inhibition of DTP, or a combination of both. In a regular killing regimen, the number of DTP cells undergoes waveform changes but remains below a baseline (Fig. 9), preventing extensive transformation to the proliferative state of ordinary cancer cells. On the other hand, continuous inhibition of DTP transformation may not reduce the basal number of DTP cells but aims to stabilize their presence at a plateau below the proliferative baseline (Fig. 9). Furthermore, a combination of both regimens may represent an optimal approach, provided that the side effects, toxicity, and economic implications of the drugs are considered.Fig. 9 DTP Burden Forecast Trends. Periodic Eliminating therapy (a) involves administering drugs to DTP cells regularly to diminish the DTP burden before it surpasses the proliferation baseline, therefore ensuring it remains below this threshold. On the other hand, continuous inhibitory therapy (b) is focused on impeding the buildup of the DTP burden and ultimately steadying the quantity of DTP cells at a plateau that is beneath the proliferative baseline

In addition to the above considerations, researchers should further investigate the interactions between anti-DTP therapy and existing anticancer therapy. Anticancer therapy primarily target signaling pathways in cancer cells, while some anti-DTP therapy also affects signaling pathways. This raises questions about potential interactions between the two types of treatment. Moreover, traditional chemotherapy could theoretically be combined with anti-DTP therapy since chemotherapy targets active cancer cells while anti-DTP therapy targets dormant DTP cells. However, a key concern is whether the DNA damage caused by chemotherapy drugs may interfere with the molecular modifications targeted by anti-DTP therapy. Both anti-DTP therapy and anticancer therapy are complex treatments with multiple mechanisms. Identifying the effective mechanisms and determining whether they can synergistically enhance each other poses a challenging but crucial opportunity to gain deeper insights into DTP cellular mechanisms.

The dose planning of drugs is also a direction that needs to be explored. In the past, adequate doses, and regular and long-term anticancer treatment were considered the best course of action. It was believed that maximizing drug dosage could prevent the development of drug resistance, akin to treating conventional bacterial infections. However, the discovery of DTP cells has challenged this assumption by weakening the established connection between drug dosage and resistance in cancer. This, in turn, raises concerns about the increased risk of side effects without a corresponding decrease in drug resistance. Therefore, pursuing research into the optimal planning of drug dosages post-combined anti-DTP and anticancer therapy holds significant promise. Further investigations should focus on gradually reducing anticancer drug therapy while inhibiting DTP cell production to prevent drug resistance from emerging.

The management of drug side effects is a crucial yet often neglected aspect of treatment. Patients commonly find the side effects of traditional chemotherapy, including hair loss, nausea, vomiting, and marrow hemopoietic suppression, to be intolerable. Moreover, the liver toxicity, nausea, diarrhea, and other adverse effects associated with anti-DTP therapy can significantly compound the discomfort experienced by patients undergoing treatment. Therefore, it is paramount to emphasize the monitoring and mitigation of side effects in the combination of anti-DTP therapy and cancer treatment regimens. Effective management of drug side effects is essential to prevent adverse effects from compounding or interacting negatively in combination therapy. Strategies should focus on minimizing side effects, such as reducing liver damage through the use of medications with different metabolic pathways.

Certainly, the essential guideline for planning anti-DTP therapy involves individualization and specific analysis of the particular problem. Anyway, a promising area for future research lies in the integration of anticancer therapy and anti-DTP therapy to develop a new comprehensive treatment for cancer. Therefore, there is a hopeful anticipation for more DTP clinical research and the development of targeted drugs for anti-DTP therapy.

Conclusion and perspective

The development of new forms of DTP cells derived from ordinary cancer cells has provided researchers with a deeper understanding of the comprehensive drug resistance mechanisms in cancer cells. This advancement goes beyond simply examining single gene mutations or random changes, allowing for a more thorough investigation into the array of drivers behind non-genetic mechanisms. This new perspective on cancer resistance challenges conventional notions and offers an opportunity to reshape the prevailing pessimism associated with relapsed and metastatic cancer. By shedding light on the comprehensive drivers of drug resistance, this innovative approach can drive progress in combating resistant cancer. However, the multi-faceted interactions of DTP cells, being non-genetic in nature, present a complex web of mechanisms contributing to drug resistance. It is evident that the diversity and interaction complexity among these mechanisms require further exploration to steadfastly advance our understanding in this area.

This review encompasses a brand range of the concept of DTP, the potential transformation process of DTP, and the comprehensive mechanism of drug resistance, and emphasizes the essential difference between the old concept of various related cancer-resistant cells and DTP cells, which exhibits a reversible inert specialization in response to external stimuli. By analyzing the common characteristic changes during DTP transformation, such as cell-cycle restriction, embryonic-like diapause, stem-like phenotype, and reversibility of transformation, it is clearly recognized that cancer cell transformation into DTP cells poses a significant challenge in anticancer therapy. Understanding the formation process of DTP cells and the development of related drug resistance mechanisms has led researchers to realize that DTP cells, although a stubborn component of cancer drug resistance, are not insurmountable obstacles. The interaction of molecular modification regulation, signaling pathways and transcription regulation, tumor micro-environment regulation, metabolic reprogramming regulation, and redox systems regulation behind the drug resistance mechanism of DTP cells has been elementary investigated. Continuous studies are identifying various targeted strategies for destroying corresponding drug resistance mechanisms. The exploration of numerous targets, in conjunction with the clinical experiment-oriented medicine model, traditional evidence-based medicine model, and traditional Chinese medicine-assisted medicine model, has led to the investigation of preclinical drugs, novel use for old drugs, and natural products within these medical paradigms to discover potential anti-DTP therapy. This exploration will serve as a key component of long-term comprehensive anticancer treatment in the future, offering new therapeutic benefits for patients with relapsed or metastatic middle and advanced cancer.

For future research, we anticipate exploring the following aspects further:Existing DTP studies primarily rely on in vitro cell tests, with some probes like Mex3a identified as potential markers15 for DTP detection in basic experiments. However, current research lacks specific indicators that could offer insights into organoids or cancer patients. To address this gap, conducting in-depth investigations into the expression patterns of molecules associated with DTP in conjunction with analyzing pathological tissues from recurrent cancer patients holds promise in providing crucial evidence for early clinical identification of DTP transformation during anticancer therapy.

Analyzing the essential differences underlying the characterization of ordinary cancer cells before transformation, transformed DTP cells, and cancer stem cells of corresponding cancer species through single cell-seq offers a more fundamental perspective. These precise analyses will directly and indirectly guide subsequent DTP studies by thoroughly separating DTP from special cells such as cancer stem cells with some plausible correlation. Additionally, the analyses will reveal how these cells emerge and exist at the micro level, shedding light on their impact on the persistence of macroscopic DTP cells.

Data collection and peak recording of DTP cells transformation curves through different drug inductions, stepped killing of drug concentrations, and corresponding DTP cells transformation curves is a crucial undertaking that demands significant effort. The induced generation of DTP cells, which is typically a minuscule fraction of the residual population following drug resistance therapy, exhibits extremely low proliferation activity and diminished responsiveness to external stimulation. The resulting scarcity at the cellular level poses challenges for cytological experiments aimed at passage, proliferation, and culture. While existing DTP research primarily focuses on reactivating DTP cells activity through drug holidays, there is a pressing need to advance the field by achieving stable induction of DTP cells production and expanding the cell population to a level conducive for in-depth studies. Enriching DTP cells sufficiently to support investigations into reactivation and proliferation dynamics under sustained external drug stimulation is key for furthering understanding in this area. Current studies have largely overlooked the importance of DTP cells enrichment and external competition due to intrinsic limitations in DTP cells quantity and challenging conditions for amplification in vitro tests. In clinical contexts, there exists a potential scenario where the quantity of DTP cells surpasses a critical threshold due to improved nutritional status and reduced immune factors, potentially lead to non-drug induced DTP reactivation amidst continued drug exposure. This shift in focus towards enriching and understanding DTP cells dynamics under varying conditions represents a critical advancement that will significantly contribute to the field of DTP research.

At present, the study of more specific and precise drug resistance mechanism targets represents a key advantage in DTP research. However, the challenges presented by the stable structure created through the interconnection and synergy among various drug resistance mechanisms should not be overlooked. By conducting a comprehensive circular analysis starting from a molecular modification regulation standpoint, researchers can gain insights into breaking through the existing resistance barriers in DTP. This approach involves examining the relationship between the influence of molecular modification regulation on upstream and downstream pathways, the proportion of components in the tumor micro-environment following overexpression or knockdown, variations in nutrient consumption and energy metabolism, and alterations in redox stability tolerance. Through this process, a better understanding of anticancer drug resistance can be established. The ultimate goal is to selectively eliminate essential components of the DTP resistant system without disrupting the body’s homeostasis, thereby significantly advancing the treatment of DTP-related cancer resistance.

In recent years, there has been a growing emphasis on research and exploration into cancer drug resistance, with DTP-related studies playing a significant role in this endeavor. DTP cells, which emerge as a result of cancer cells undergoing specialized adaptations in response to drug exposure, represent a distinct subgroup of cancer cells that exhibit pivotal non-genetic characteristics in comparison with those seen in various cancer cell lineages. Despite their diverse origins, DTP cells undergo a series of dynamic transformations that can be intricately studied. This detailed examination of DTP cells not only offers valuable insights into cancer drug resistance at a fundamental level but also provides a method for addressing drug resistance in practical applications. By bridging the gap between basic and applied research, the comprehensive investigation of DTP cells holds promise for advancing our understanding of cancer drug resistance and, ultimately, enhancing patient outcomes in oncology.

Acknowledgements

We are grateful to all the researchers who have contributed to the field of cancer drug resistance and DTP cells. Thanks for the help of the website Figdraw in drawing the components of the figures.

Author contributions

Xinbing Sui, Xiaohong Xie, and Qinsong Sheng guided and designed this review. Jun He wrote the original manuscript and drew the figures and tables. Zejing Qiu and Jingjing Fan performed the data collection. All authors read and approved the article.

Competing interests

The authors declare no competing interests.
==== Refs
References

1. Maemondo M Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl. J. Med. 2010 362 2380 2388 10.1056/NEJMoa0909530 20573926
Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).20573926 10.1056/NEJMoa0909530
2. Ogino A Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line Cancer Res 2007 67 7807 7814 10.1158/0008-5472.CAN-07-0681 17699786
Ogino, A. et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 67, 7807–7814 (2007).17699786 10.1158/0008-5472.CAN-07-0681
3. Oxnard GR Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to Osimertinib JAMA Oncol. 2018 4 1527 1534 10.1001/jamaoncol.2018.2969 30073261
Oxnard, G. R. et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to Osimertinib. JAMA Oncol. 4, 1527–1534 (2018).30073261 10.1001/jamaoncol.2018.2969
4. Pu Y Drug-tolerant persister cells in cancer: the cutting edges and future directions Nat. Rev. Clin. Oncol. 2023 20 799 813 10.1038/s41571-023-00815-5 37749382
Pu, Y. et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat. Rev. Clin. Oncol. 20, 799–813 (2023).37749382 10.1038/s41571-023-00815-5
5. Nilsson MB CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance Cancer Cell 2023 41 340 355.e6 10.1016/j.ccell.2023.01.007 36787696
Nilsson, M. B. et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell 41, 340–355.e6 (2023).36787696 10.1016/j.ccell.2023.01.007
6. Isozaki H Therapy-induced APOBEC3A drives evolution of persistent cancer cells Nature 2023 620 393 401 10.1038/s41586-023-06303-1 37407818
Isozaki, H. et al. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature 620, 393–401 (2023).37407818 10.1038/s41586-023-06303-1
7. Oren Y Cycling cancer persister cells arise from lineages with distinct programs Nature 2021 596 576 582 10.1038/s41586-021-03796-6 34381210
Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576–582 (2021).34381210 10.1038/s41586-021-03796-6
8. Hangauer MJ Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition Nature 2017 551 247 250 10.1038/nature24297 29088702
Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247–250 (2017).29088702 10.1038/nature24297
9. Liu X Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells EBioMedicine 2023 90 104496 10.1016/j.ebiom.2023.104496 36863257
Liu, X. et al. Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells. EBioMedicine 90, 104496 (2023).36863257 10.1016/j.ebiom.2023.104496
10. Wu Y-C Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis Aging 2024 16 627 647 38206305
Wu, Y.-C. et al. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis. Aging 16, 627–647 (2024).38206305
11. Daley BR SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status Proc. Natl Acad. Sci. USA 2023 120 e2313137120 10.1073/pnas.2313137120 37972068
Daley, B. R. et al. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Proc. Natl Acad. Sci. USA 120, e2313137120 (2023).37972068 10.1073/pnas.2313137120
12. Furugaki K FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes Npj Precis. Oncol. 2023 7 1 15 36593350
Furugaki, K. et al. FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes. Npj Precis. Oncol. 7, 1–15 (2023).36593350
13. Rehman SK Colorectal cancer cells enter a Diapause-like DTP state to survive chemotherapy Cell 2021 184 226 242.e21 10.1016/j.cell.2020.11.018 33417860
Rehman, S. K. et al. Colorectal cancer cells enter a Diapause-like DTP state to survive chemotherapy. Cell 184, 226–242.e21 (2021).33417860 10.1016/j.cell.2020.11.018
14. You JH Lee J Roh J-L PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells J. Exp. Clin. Cancer Res. CR 2021 40 350 10.1186/s13046-021-02168-2 34749765
You, J. H., Lee, J. & Roh, J.-L. PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells. J. Exp. Clin. Cancer Res. CR 40, 350 (2021).34749765 10.1186/s13046-021-02168-2
15. Álvarez-Varela A Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy Nat. Cancer 2022 3 1052 1070 10.1038/s43018-022-00402-0 35773527
Álvarez-Varela, A. et al. Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nat. Cancer 3, 1052–1070 (2022).35773527 10.1038/s43018-022-00402-0
16. Moghal N Single-cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung Adenocarcinoma Xenograft Model J. Thorac. Oncol. 2023 18 499 515 10.1016/j.jtho.2022.12.003 36535627
Moghal, N. et al. Single-cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung Adenocarcinoma Xenograft Model. J. Thorac. Oncol. 18, 499–515 (2023).36535627 10.1016/j.jtho.2022.12.003
17. Tanaka K Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis Cancer Cell 2021 39 1245 1261.e6 10.1016/j.ccell.2021.07.006 34388376
Tanaka, K. et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell 39, 1245–1261.e6 (2021).34388376 10.1016/j.ccell.2021.07.006
18. Glasheen MQ Targeting upregulated cIAP2 in SOX10-deficient drug tolerant melanoma Mol. Cancer Ther. 2023 22 1087 1099 10.1158/1535-7163.MCT-23-0025 37343247
Glasheen, M. Q. et al. Targeting upregulated cIAP2 in SOX10-deficient drug tolerant melanoma. Mol. Cancer Ther. 22, 1087–1099 (2023).37343247 10.1158/1535-7163.MCT-23-0025
19. PLOUGH HH Penicillin resistance of Staphylococcus aureus and its clinical implications Am. J. Clin. Pathol. 1945 15 446 451 10.1093/ajcp/15.10.446 21005048
PLOUGH, H. H. Penicillin resistance of Staphylococcus aureus and its clinical implications. Am. J. Clin. Pathol. 15, 446–451 (1945).21005048 10.1093/ajcp/15.10.446
20. Beckman H Penicillin resistance Wis. Med. J. 1947 46 621 20243352
Beckman, H. Penicillin resistance. Wis. Med. J. 46, 621 (1947).20243352
21. Bishop A Drug-resistance in malaria Br. Med. Bull. 1951 8 47 50 10.1093/oxfordjournals.bmb.a074053 14944814
Bishop, A. Drug-resistance in malaria. Br. Med. Bull. 8, 47–50 (1951).14944814 10.1093/oxfordjournals.bmb.a074053
22. Cavalli LL Genetic analysis of drug-resistance Bull. World Health Organ. 1952 6 185 206 14954420
Cavalli, L. L. Genetic analysis of drug-resistance. Bull. World Health Organ. 6, 185–206 (1952).14954420
23. Davis BD Bacterial genetics and drug resistance Public Health Rep. Wash. DC 1896 1952 67 376 379 10.2307/4588082
Davis, B. D. Bacterial genetics and drug resistance. Public Health Rep. Wash. DC 1896 67, 376–379 (1952).10.2307/4588082
24. Smith PA Romesberg FE Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation Nat. Chem. Biol. 2007 3 549 556 10.1038/nchembio.2007.27 17710101
Smith, P. A. & Romesberg, F. E. Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. Nat. Chem. Biol. 3, 549–556 (2007).17710101 10.1038/nchembio.2007.27
25. LAW LW Differences between cancers in terms of evolution of drug resistance Cancer Res 1956 16 698 716 13356297
LAW, L. W. Differences between cancers in terms of evolution of drug resistance. Cancer Res 16, 698–716 (1956).13356297
26. Vicente M The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol. Rev. 2006 30 841 852 10.1111/j.1574-6976.2006.00038.x 17064283
Vicente, M. et al. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol. Rev. 30, 841–852 (2006).17064283 10.1111/j.1574-6976.2006.00038.x
27. Iorio F A Landscape of Pharmacogenomic Interactions in Cancer Cell 2016 166 740 754 10.1016/j.cell.2016.06.017 27397505
Iorio, F. et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 166, 740–754 (2016).27397505 10.1016/j.cell.2016.06.017
28. Misale S Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 2012 486 532 536 10.1038/nature11156 22722830
Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012).22722830 10.1038/nature11156
29. Wang Y BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance Nat. Commun. 2019 10 5661 10.1038/s41467-019-13530-6 31827092
Wang, Y. et al. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nat. Commun. 10, 5661 (2019).31827092 10.1038/s41467-019-13530-6
30. Virappane P Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party J. Clin. Oncol. 2008 26 5429 5435 10.1200/JCO.2008.16.0333 18591546
Virappane, P. et al. Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J. Clin. Oncol. 26, 5429–5435 (2008).18591546 10.1200/JCO.2008.16.0333
31. Inukai M Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer Cancer Res 2006 66 7854 7858 10.1158/0008-5472.CAN-06-1951 16912157
Inukai, M. et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66, 7854–7858 (2006).16912157 10.1158/0008-5472.CAN-06-1951
32. Sharma SV A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 2010 141 69 80 10.1016/j.cell.2010.02.027 20371346
Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).20371346 10.1016/j.cell.2010.02.027
33. Zhang X Glutathione Peroxidase 4 as a therapeutic target for anti-colorectal cancer drug-tolerant persister cells Front. Oncol. 2022 12 913669 10.3389/fonc.2022.913669 35719967
Zhang, X. et al. Glutathione Peroxidase 4 as a therapeutic target for anti-colorectal cancer drug-tolerant persister cells. Front. Oncol. 12, 913669 (2022).35719967 10.3389/fonc.2022.913669
34. Mikubo M Inoue Y Liu G Tsao M-S Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy J. Thorac. Oncol. 2021 16 1798 1809 10.1016/j.jtho.2021.07.017 34352380
Mikubo, M., Inoue, Y., Liu, G. & Tsao, M.-S. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J. Thorac. Oncol. 16, 1798–1809 (2021).34352380 10.1016/j.jtho.2021.07.017
35. McNeer NA Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia Leukemia 2019 33 1934 1943 10.1038/s41375-019-0402-3 30760869
McNeer, N. A. et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia 33, 1934–1943 (2019).30760869 10.1038/s41375-019-0402-3
36. Bailey C Shoura MJ Mischel PS Swanton C Extrachromosomal DNA-relieving heredity constraints, accelerating tumour evolution Ann. Oncol. 2020 31 884 893 10.1016/j.annonc.2020.03.303 32275948
Bailey, C., Shoura, M. J., Mischel, P. S. & Swanton, C. Extrachromosomal DNA-relieving heredity constraints, accelerating tumour evolution. Ann. Oncol. 31, 884–893 (2020).32275948 10.1016/j.annonc.2020.03.303
37. Dagogo-Jack I Shaw AT Tumour heterogeneity and resistance to cancer therapies Nat. Rev. Clin. Oncol. 2018 15 81 94 10.1038/nrclinonc.2017.166 29115304
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).29115304 10.1038/nrclinonc.2017.166
38. Anurag M Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer Cancer Discov. 2022 12 2586 2605 10.1158/2159-8290.CD-22-0200 36001024
Anurag, M. et al. Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer. Cancer Discov. 12, 2586–2605 (2022).36001024 10.1158/2159-8290.CD-22-0200
39. Turner NC Reis-Filho JS Genetic heterogeneity and cancer drug resistance Lancet Oncol. 2012 13 e178 e185 10.1016/S1470-2045(11)70335-7 22469128
Turner, N. C. & Reis-Filho, J. S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 13, e178–e185 (2012).22469128 10.1016/S1470-2045(11)70335-7
40. Goyal Y Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells Nature 2023 620 651 659 10.1038/s41586-023-06342-8 37468627
Goyal, Y. et al. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature 620, 651–659 (2023).37468627 10.1038/s41586-023-06342-8
41. Raha D The cancer stem cell marker aldehyde Dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation Cancer Res. 2014 74 3579 3590 10.1158/0008-5472.CAN-13-3456 24812274
Raha, D. et al. The cancer stem cell marker aldehyde Dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res. 74, 3579–3590 (2014).24812274 10.1158/0008-5472.CAN-13-3456
42. Aissa AF Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer Nat. Commun. 2021 12 1628 10.1038/s41467-021-21884-z 33712615
Aissa, A. F. et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat. Commun. 12, 1628 (2021).33712615 10.1038/s41467-021-21884-z
43. Baharoglu Z Mazel D SOS, the formidable strategy of bacteria against aggressions FEMS Microbiol. Rev. 2014 38 1126 1145 10.1111/1574-6976.12077 24923554
Baharoglu, Z. & Mazel, D. SOS, the formidable strategy of bacteria against aggressions. FEMS Microbiol. Rev. 38, 1126–1145 (2014).24923554 10.1111/1574-6976.12077
44. Witkin EM Elevated mutability of polA derivatives of Escherichia coli B/r at sublethal doses of ultraviolet light: evidence for an inducible error-prone repair system (‘SOS repair’) and its anomalous expression in these strains Genetics 1975 79 199 213 1097302
Witkin, E. M. Elevated mutability of polA derivatives of Escherichia coli B/r at sublethal doses of ultraviolet light: evidence for an inducible error-prone repair system (‘SOS repair’) and its anomalous expression in these strains. Genetics 79, 199–213 (1975).1097302
45. Al Mamun AAM Identity and function of a large gene network underlying mutagenic repair of DNA breaks Science 2012 338 1344 1348 10.1126/science.1226683 23224554
Al Mamun, A. A. M. et al. Identity and function of a large gene network underlying mutagenic repair of DNA breaks. Science 338, 1344–1348 (2012).23224554 10.1126/science.1226683
46. Fitzgerald DM Hastings PJ Rosenberg SM Stress-induced mutagenesis: implications in cancer and drug resistance Annu. Rev. Cancer Biol. 2017 1 119 140 10.1146/annurev-cancerbio-050216-121919 29399660
Fitzgerald, D. M., Hastings, P. J. & Rosenberg, S. M. Stress-induced mutagenesis: implications in cancer and drug resistance. Annu. Rev. Cancer Biol. 1, 119–140 (2017).29399660 10.1146/annurev-cancerbio-050216-121919
47. Russo M Adaptive mutability of colorectal cancers in response to targeted therapies Science 2019 366 1473 1480 10.1126/science.aav4474 31699882
Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473–1480 (2019).31699882 10.1126/science.aav4474
48. Cipponi A MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer Science 2020 368 1127 1131 10.1126/science.aau8768 32499442
Cipponi, A. et al. MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. Science 368, 1127–1131 (2020).32499442 10.1126/science.aau8768
49. Echeverria GV Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state Sci. Transl. Med. 2019 11 eaav0936 10.1126/scitranslmed.aav0936 30996079
Echeverria, G. V. et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci. Transl. Med. 11, eaav0936 (2019).30996079 10.1126/scitranslmed.aav0936
50. Shaffer SM Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance Nature 2017 546 431 435 10.1038/nature22794 28607484
Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431–435 (2017).28607484 10.1038/nature22794
51. Dhimolea E An embryonic Diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence Cancer Cell 2021 39 240 256.e11 10.1016/j.ccell.2020.12.002 33417832
Dhimolea, E. et al. An embryonic Diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell 39, 240–256.e11 (2021).33417832 10.1016/j.ccell.2020.12.002
52. Dobson SM Relapse-fated latent diagnosis subclones in acute B lineage leukemia are drug tolerant and possess distinct metabolic programs Cancer Discov. 2020 10 568 587 10.1158/2159-8290.CD-19-1059 32086311
Dobson, S. M. et al. Relapse-fated latent diagnosis subclones in acute B lineage leukemia are drug tolerant and possess distinct metabolic programs. Cancer Discov. 10, 568–587 (2020).32086311 10.1158/2159-8290.CD-19-1059
53. Kobayashi I Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells Biochem. Biophys. Res. Commun. 2016 473 125 132 10.1016/j.bbrc.2016.03.064 26996130
Kobayashi, I. et al. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. Biochem. Biophys. Res. Commun. 473, 125–132 (2016).26996130 10.1016/j.bbrc.2016.03.064
54. Wang Z Meng F Zhong Z Emerging targeted drug delivery strategies toward ovarian cancer Adv. Drug Deliv. Rev. 2021 178 113969 10.1016/j.addr.2021.113969 34509574
Wang, Z., Meng, F. & Zhong, Z. Emerging targeted drug delivery strategies toward ovarian cancer. Adv. Drug Deliv. Rev. 178, 113969 (2021).34509574 10.1016/j.addr.2021.113969
55. Rambow F Toward minimal residual disease-directed therapy in melanoma Cell 2018 174 843 855.e19 10.1016/j.cell.2018.06.025 30017245
Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843–855.e19 (2018).30017245 10.1016/j.cell.2018.06.025
56. Shen S Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation Cell Rep. 2020 33 108421 10.1016/j.celrep.2020.108421 33238129
Shen, S. et al. Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep. 33, 108421 (2020).33238129 10.1016/j.celrep.2020.108421
57. Müller S CD44 regulates epigenetic plasticity by mediating iron endocytosis Nat. Chem. 2020 12 929 938 10.1038/s41557-020-0513-5 32747755
Müller, S. et al. CD44 regulates epigenetic plasticity by mediating iron endocytosis. Nat. Chem. 12, 929–938 (2020).32747755 10.1038/s41557-020-0513-5
58. Bell CC Gilan O Principles and mechanisms of non-genetic resistance in cancer Br. J. Cancer 2020 122 465 472 10.1038/s41416-019-0648-6 31831859
Bell, C. C. & Gilan, O. Principles and mechanisms of non-genetic resistance in cancer. Br. J. Cancer 122, 465–472 (2020).31831859 10.1038/s41416-019-0648-6
59. Liau BB Adaptive Chromatin remodeling drives Glioblastoma stem cell plasticity and drug tolerance Cell Stem Cell 2017 20 233 246.e7 10.1016/j.stem.2016.11.003 27989769
Liau, B. B. et al. Adaptive Chromatin remodeling drives Glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20, 233–246.e7 (2017).27989769 10.1016/j.stem.2016.11.003
60. Guler GD Repression of stress-induced LINE-1 Expression protects cancer cell subpopulations from lethal drug exposure Cancer Cell 2017 32 221 237.e13 10.1016/j.ccell.2017.07.002 28781121
Guler, G. D. et al. Repression of stress-induced LINE-1 Expression protects cancer cell subpopulations from lethal drug exposure. Cancer Cell 32, 221–237.e13 (2017).28781121 10.1016/j.ccell.2017.07.002
61. Criscione SW The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells Npj Precis. Oncol. 2022 6 95 10.1038/s41698-022-00337-w 36575215
Criscione, S. W. et al. The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. Npj Precis. Oncol. 6, 95 (2022).36575215 10.1038/s41698-022-00337-w
62. Numata H Shintani Y Diapause in univoltine and semivoltine life cycles Annu. Rev. Entomol. 2023 68 257 276 10.1146/annurev-ento-120220-101047 36198404
Numata, H. & Shintani, Y. Diapause in univoltine and semivoltine life cycles. Annu. Rev. Entomol. 68, 257–276 (2023).36198404 10.1146/annurev-ento-120220-101047
63. Lin Y-H Zhu H A malignant case of arrested development: cancer cell dormancy mimics embryonic diapause Cancer Cell 2021 39 142 144 10.1016/j.ccell.2021.01.013 33561394
Lin, Y.-H. & Zhu, H. A malignant case of arrested development: cancer cell dormancy mimics embryonic diapause. Cancer Cell 39, 142–144 (2021).33561394 10.1016/j.ccell.2021.01.013
64. Deng L Research advances on embryonic diapause in mammals Anim. Reprod. Sci. 2018 198 1 10 10.1016/j.anireprosci.2018.09.009 30266523
Deng, L. et al. Research advances on embryonic diapause in mammals. Anim. Reprod. Sci. 198, 1–10 (2018).30266523 10.1016/j.anireprosci.2018.09.009
65. Prasetyanti PR Medema JP Intra-tumor heterogeneity from a cancer stem cell perspective Mol. Cancer 2017 16 41 10.1186/s12943-017-0600-4 28209166
Prasetyanti, P. R. & Medema, J. P. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol. Cancer 16, 41 (2017).28209166 10.1186/s12943-017-0600-4
66. Medema JP Cancer stem cells: The challenges ahead Nat. Cell Biol. 2013 15 338 344 10.1038/ncb2717 23548926
Medema, J. P. Cancer stem cells: The challenges ahead. Nat. Cell Biol. 15, 338–344 (2013).23548926 10.1038/ncb2717
67. Arasada RR Amann JM Rahman MA Huppert SS Carbone DP EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling Cancer Res. 2014 74 5572 5584 10.1158/0008-5472.CAN-13-3724 25125655
Arasada, R. R., Amann, J. M., Rahman, M. A., Huppert, S. S. & Carbone, D. P. EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer Res. 74, 5572–5584 (2014).25125655 10.1158/0008-5472.CAN-13-3724
68. Prabavathy D Swarnalatha Y Ramadoss N Lung cancer stem cells-origin, characteristics and therapy Stem Cell Investig. 2018 5 6 10.21037/sci.2018.02.01 29682513
Prabavathy, D., Swarnalatha, Y. & Ramadoss, N. Lung cancer stem cells-origin, characteristics and therapy. Stem Cell Investig. 5, 6 (2018).29682513 10.21037/sci.2018.02.01
69. Adamski V Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment Oncotarget 2017 8 108064 108078 10.18632/oncotarget.22514 29296224
Adamski, V. et al. Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment. Oncotarget 8, 108064–108078 (2017).29296224 10.18632/oncotarget.22514
70. Ravindran Menon D A stress-induced early innate response causes multidrug tolerance in melanoma Oncogene 2015 34 4448 4459 10.1038/onc.2014.372 25417704
Ravindran Menon, D. et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene 34, 4448–4459 (2015).25417704 10.1038/onc.2014.372
71. Alowaidi F Assessing stemness and proliferation properties of the newly established colon cancer ‘stem’ cell line, CSC480, and novel approaches to identify dormant cancer cells Oncol. Rep. 2018 39 2881 2891 29693155
Alowaidi, F. et al. Assessing stemness and proliferation properties of the newly established colon cancer ‘stem’ cell line, CSC480, and novel approaches to identify dormant cancer cells. Oncol. Rep. 39, 2881–2891 (2018).29693155
72. Bai X Ni J Beretov J Graham P Li Y Cancer stem cell in breast cancer therapeutic resistance Cancer Treat. Rev. 2018 69 152 163 10.1016/j.ctrv.2018.07.004 30029203
Bai, X., Ni, J., Beretov, J., Graham, P. & Li, Y. Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat. Rev. 69, 152–163 (2018).30029203 10.1016/j.ctrv.2018.07.004
73. Carcereri de Prati A Metastatic breast cancer cells enter into dormant state and express cancer stem cells phenotype under chronic hypoxia J. Cell. Biochem 2017 118 3237 3248 10.1002/jcb.25972 28262977
Carcereri de Prati, A. et al. Metastatic breast cancer cells enter into dormant state and express cancer stem cells phenotype under chronic hypoxia. J. Cell. Biochem 118, 3237–3248 (2017).28262977 10.1002/jcb.25972
74. Zhang X Han Z-Y Chen Y Prostate cancer stem cells: Current understanding Zhonghua Nan Ke Xue Natl J. Androl. 2021 27 172 176
Zhang, X., Han, Z.-Y. & Chen, Y. Prostate cancer stem cells: Current understanding. Zhonghua Nan Ke Xue Natl J. Androl. 27, 172–176 (2021).
75. Zhou N Stem cell characteristics of dormant cells and cisplatin‑induced effects on the stemness of epithelial ovarian cancer cells Mol. Med. Rep. 2014 10 2495 2504 10.3892/mmr.2014.2483 25119644
Zhou, N. et al. Stem cell characteristics of dormant cells and cisplatin‑induced effects on the stemness of epithelial ovarian cancer cells. Mol. Med. Rep. 10, 2495–2504 (2014).25119644 10.3892/mmr.2014.2483
76. Rahman M The cancer stem cell hypothesis: failures and pitfalls Neurosurgery 2011 68 531 545 10.1227/NEU.0b013e3181ff9eb5 21135745
Rahman, M. et al. The cancer stem cell hypothesis: failures and pitfalls. Neurosurgery 68, 531–545 (2011).21135745 10.1227/NEU.0b013e3181ff9eb5
77. Zheng H Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer Stem Cell Res. Ther. 2022 13 244 10.1186/s13287-022-02913-0 35681225
Zheng, H. et al. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer. Stem Cell Res. Ther. 13, 244 (2022).35681225 10.1186/s13287-022-02913-0
78. Roesch A Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells Cancer Cell 2013 23 811 825 10.1016/j.ccr.2013.05.003 23764003
Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23, 811–825 (2013).23764003 10.1016/j.ccr.2013.05.003
79. Huang W Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles Eur. J. Med. Chem. 2022 232 114207 10.1016/j.ejmech.2022.114207 35219948
Huang, W. et al. Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles. Eur. J. Med. Chem. 232, 114207 (2022).35219948 10.1016/j.ejmech.2022.114207
80. Liu Y Azizian NG Sullivan DK Li Y mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters Nat. Commun. 2022 13 7047 10.1038/s41467-022-34890-6 36396656
Liu, Y., Azizian, N. G., Sullivan, D. K. & Li, Y. mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters. Nat. Commun. 13, 7047 (2022).36396656 10.1038/s41467-022-34890-6
81. Chang CA Ontogeny and vulnerabilities of drug-tolerant persisters in HER2+ breast cancer Cancer Discov. 2022 12 1022 1045 10.1158/2159-8290.CD-20-1265 34911733
Chang, C. A. et al. Ontogeny and vulnerabilities of drug-tolerant persisters in HER2+ breast cancer. Cancer Discov. 12, 1022–1045 (2022).34911733 10.1158/2159-8290.CD-20-1265
82. Colombo N Gore M Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy Crit. Rev. Oncol. Hematol. 2007 64 129 138 10.1016/j.critrevonc.2007.04.004 17566758
Colombo, N. & Gore, M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit. Rev. Oncol. Hematol. 64, 129–138 (2007).17566758 10.1016/j.critrevonc.2007.04.004
83. Hejna M Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer Br. J. Cancer 1998 78 760 764 10.1038/bjc.1998.574 9743296
Hejna, M. et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br. J. Cancer 78, 760–764 (1998).9743296 10.1038/bjc.1998.574
84. Simon GR Wagner H American College of Chest Physicians. Small cell lung cancer Chest 2003 123 259S 271S 10.1378/chest.123.1_suppl.259S 12527584
Simon, G. R., Wagner, H. & American College of Chest Physicians. Small cell lung cancer. Chest 123, 259S–271S (2003).12527584 10.1378/chest.123.1_suppl.259S
85. Pettitt GA Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro J. Pathol. 2023 259 220 232 10.1002/path.6034 36385700
Pettitt, G. A. et al. Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro. J. Pathol. 259, 220–232 (2023).36385700 10.1002/path.6034
86. Cara S Tannock IF Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance Ann. Oncol. 2001 12 23 27 10.1023/A:1008389706725 11249045
Cara, S. & Tannock, I. F. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann. Oncol. 12, 23–27 (2001).11249045 10.1023/A:1008389706725
87. Kuczynski EA Sargent DJ Grothey A Kerbel RS Drug rechallenge and treatment beyond progression—implications for drug resistance Nat. Rev. Clin. Oncol. 2013 10 571 587 10.1038/nrclinonc.2013.158 23999218
Kuczynski, E. A., Sargent, D. J., Grothey, A. & Kerbel, R. S. Drug rechallenge and treatment beyond progression—implications for drug resistance. Nat. Rev. Clin. Oncol. 10, 571–587 (2013).23999218 10.1038/nrclinonc.2013.158
88. Sun X The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity Cell Metab. 2023 35 1563 1579.e8 10.1016/j.cmet.2023.07.005 37543034
Sun, X. et al. The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity. Cell Metab. 35, 1563–1579.e8 (2023).37543034 10.1016/j.cmet.2023.07.005
89. Liu J Niu N Li X Zhang X Sood AK The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions Semin. Cancer Biol. 2022 81 132 144 10.1016/j.semcancer.2021.10.005 34670140
Liu, J., Niu, N., Li, X., Zhang, X. & Sood, A. K. The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Semin. Cancer Biol. 81, 132–144 (2022).34670140 10.1016/j.semcancer.2021.10.005
90. Easwaran S Montell DJ The molecular mechanisms of diapause and diapause-like reversible arrest Biochem. Soc. Trans. 2023 51 1847 1856 10.1042/BST20221431 37800560
Easwaran, S. & Montell, D. J. The molecular mechanisms of diapause and diapause-like reversible arrest. Biochem. Soc. Trans. 51, 1847–1856 (2023).37800560 10.1042/BST20221431
91. Hussein AM Balachandar N Mathieu J Ruohola-Baker H Molecular regulators of embryonic diapause and cancer diapause-like state Cells 2022 11 2929 10.3390/cells11192929 36230891
Hussein, A. M., Balachandar, N., Mathieu, J. & Ruohola-Baker, H. Molecular regulators of embryonic diapause and cancer diapause-like state. Cells 11, 2929 (2022).36230891 10.3390/cells11192929
92. Keshri R Mathieu J Ruohola-Baker H Fight, flight, and freeze! Cell Metab. 2023 35 1493 1495 10.1016/j.cmet.2023.08.007 37673033
Keshri, R., Mathieu, J. & Ruohola-Baker, H. Fight, flight, and freeze! Cell Metab. 35, 1493–1495 (2023).37673033 10.1016/j.cmet.2023.08.007
93. Anand P Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL Blood 2021 137 2463 2480 10.1182/blood.2019004547 33227818
Anand, P. et al. Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood 137, 2463–2480 (2021).33227818 10.1182/blood.2019004547
94. Basu S Dong Y Kumar R Jeter C Tang DG Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis Semin. Cancer Biol. 2022 78 90 103 10.1016/j.semcancer.2021.04.021 33979674
Basu, S., Dong, Y., Kumar, R., Jeter, C. & Tang, D. G. Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis. Semin. Cancer Biol. 78, 90–103 (2022).33979674 10.1016/j.semcancer.2021.04.021
95. Davis JE Kirk J Ji Y Tang DG Tumor dormancy and slow-cycling cancer cells Adv. Exp. Med. Biol. 2019 1164 199 206 10.1007/978-3-030-22254-3_15 31576550
Davis, J. E., Kirk, J., Ji, Y. & Tang, D. G. Tumor dormancy and slow-cycling cancer cells. Adv. Exp. Med. Biol. 1164, 199–206 (2019).31576550 10.1007/978-3-030-22254-3_15
96. Vallette FM Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer Biochem. Pharmacol. 2019 162 169 176 10.1016/j.bcp.2018.11.004 30414937
Vallette, F. M. et al. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Biochem. Pharmacol. 162, 169–176 (2019).30414937 10.1016/j.bcp.2018.11.004
97. Szebényi K Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother. 2023 71 101007
Szebényi, K. et al. Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells. Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother. 71, 101007 (2023).
98. Cheng X Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6-Cyclin D1 axis to drive tumorigenesis and drug resistance Cancer Res. 2023 83 2839 2857 10.1158/0008-5472.CAN-22-3558 37272756
Cheng, X. et al. Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6-Cyclin D1 axis to drive tumorigenesis and drug resistance. Cancer Res. 83, 2839–2857 (2023).37272756 10.1158/0008-5472.CAN-22-3558
99. Alors-Perez E Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug J. Exp. Clin. Cancer Res. CR 2021 40 382 10.1186/s13046-021-02153-9 34857016
Alors-Perez, E. et al. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. J. Exp. Clin. Cancer Res. CR 40, 382 (2021).34857016 10.1186/s13046-021-02153-9
100. Katsuno Y Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition Sci. Signal. 2019 12 eaau8544 10.1126/scisignal.aau8544 30808819
Katsuno, Y. et al. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci. Signal. 12, eaau8544 (2019).30808819 10.1126/scisignal.aau8544
101. Kwon J-W Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency Mol. Cancer 2023 22 156 10.1186/s12943-023-01857-0 37730636
Kwon, J.-W. et al. Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency. Mol. Cancer 22, 156 (2023).37730636 10.1186/s12943-023-01857-0
102. Reisenauer KN Therapeutic vulnerabilities of cancer stem cells and effects of natural products Nat. Prod. Rep. 2023 40 1432 1456 10.1039/D3NP00002H 37103550
Reisenauer, K. N. et al. Therapeutic vulnerabilities of cancer stem cells and effects of natural products. Nat. Prod. Rep. 40, 1432–1456 (2023).37103550 10.1039/D3NP00002H
103. Li M FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters J. Clin. Invest. 2023 133 e166666 10.1172/JCI166666 37966117
Li, M. et al. FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters. J. Clin. Invest. 133, e166666 (2023).37966117 10.1172/JCI166666
104. Tape CJ Plastic persisters: revival stem cells in colorectal cancer Trends Cancer 2024 10 185 195 10.1016/j.trecan.2023.11.003 38071119
Tape, C. J. Plastic persisters: revival stem cells in colorectal cancer. Trends Cancer 10, 185–195 (2024).38071119 10.1016/j.trecan.2023.11.003
105. Qin X An oncogenic phenoscape of colonic stem cell polarization Cell 2023 186 5554 5568.e18 10.1016/j.cell.2023.11.004 38065080
Qin, X. et al. An oncogenic phenoscape of colonic stem cell polarization. Cell 186, 5554–5568.e18 (2023).38065080 10.1016/j.cell.2023.11.004
106. Shibue T Weinberg RA EMT, CSCs, and drug resistance: The mechanistic link and clinical implications Nat. Rev. Clin. Oncol. 2017 14 611 629 10.1038/nrclinonc.2017.44 28397828
Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611–629 (2017).28397828 10.1038/nrclinonc.2017.44
107. Boumahdi S de Sauvage FJ The great escape: Tumour cell plasticity in resistance to targeted therapy Nat. Rev. Drug Discov. 2020 19 39 56 10.1038/s41573-019-0044-1 31601994
Boumahdi, S. & de Sauvage, F. J. The great escape: Tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39–56 (2020).31601994 10.1038/s41573-019-0044-1
108. Liu X Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis Cell Death Dis. 2023 14 370 10.1038/s41419-023-05888-9 37353480
Liu, X. et al. Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis. Cell Death Dis. 14, 370 (2023).37353480 10.1038/s41419-023-05888-9
109. Mauro-Lizcano M Sotgia F Lisanti MP SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production Aging 2022 14 9877 9889 10.18632/aging.204452 36566021
Mauro-Lizcano, M., Sotgia, F. & Lisanti, M. P. SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production. Aging 14, 9877–9889 (2022).36566021 10.18632/aging.204452
110. Fiorillo M Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs) Aging 2016 8 1593 1607 10.18632/aging.100983 27344270
Fiorillo, M. et al. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging 8, 1593–1607 (2016).27344270 10.18632/aging.100983
111. Jacob Berger A IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy Nat. Cancer 2021 2 1055 1070 10.1038/s43018-021-00261-1 35121883
Jacob Berger, A. et al. IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy. Nat. Cancer 2, 1055–1070 (2021).35121883 10.1038/s43018-021-00261-1
112. Ramirez M Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells Nat. Commun. 2016 7 10690 10.1038/ncomms10690 26891683
Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).26891683 10.1038/ncomms10690
113. Shen S Vagner S Robert C Persistent cancer cells: the deadly survivors Cell 2020 183 860 874 10.1016/j.cell.2020.10.027 33186528
Shen, S., Vagner, S. & Robert, C. Persistent cancer cells: the deadly survivors. Cell 183, 860–874 (2020).33186528 10.1016/j.cell.2020.10.027
114. Vitale I Manic G Coussens LM Kroemer G Galluzzi L Macrophages and metabolism in the tumor microenvironment Cell Metab. 2019 30 36 50 10.1016/j.cmet.2019.06.001 31269428
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. & Galluzzi, L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019).31269428 10.1016/j.cmet.2019.06.001
115. Elia I Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells Cell Metab. 2022 34 1137 1150.e6 10.1016/j.cmet.2022.06.008 35820416
Elia, I. et al. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells. Cell Metab. 34, 1137–1150.e6 (2022).35820416 10.1016/j.cmet.2022.06.008
116. Daveri E Adamo AM Alfine E Zhu W Oteiza PI Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway Redox Biol. 2021 38 101830 10.1016/j.redox.2020.101830 33338921
Daveri, E., Adamo, A. M., Alfine, E., Zhu, W. & Oteiza, P. I. Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway. Redox Biol. 38, 101830 (2021).33338921 10.1016/j.redox.2020.101830
117. Butturini E Carcereri de Prati A Mariotto S Redox regulation of STAT1 and STAT3 signaling Int. J. Mol. Sci. 2020 21 7034 10.3390/ijms21197034 32987855
Butturini, E., Carcereri de Prati, A. & Mariotto, S. Redox regulation of STAT1 and STAT3 signaling. Int. J. Mol. Sci. 21, 7034 (2020).32987855 10.3390/ijms21197034
118. Ma X CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability Cell Metab. 2021 33 1001 1012.e5 10.1016/j.cmet.2021.02.015 33691090
Ma, X. et al. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability. Cell Metab. 33, 1001–1012.e5 (2021).33691090 10.1016/j.cmet.2021.02.015
119. Xu S Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors Immunity 2021 54 1561 1577.e7 10.1016/j.immuni.2021.05.003 34102100
Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity 54, 1561–1577.e7 (2021).34102100 10.1016/j.immuni.2021.05.003
120. Heide T The co-evolution of the genome and epigenome in colorectal cancer Nature 2022 611 733 743 10.1038/s41586-022-05202-1 36289335
Heide, T. et al. The co-evolution of the genome and epigenome in colorectal cancer. Nature 611, 733–743 (2022).36289335 10.1038/s41586-022-05202-1
121. Ghandi M Next-generation characterization of the Cancer Cell Line Encyclopedia Nature 2019 569 503 508 10.1038/s41586-019-1186-3 31068700
Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503–508 (2019).31068700 10.1038/s41586-019-1186-3
122. Pfister SX Ashworth A Marked for death: Targeting epigenetic changes in cancer Nat. Rev. Drug Discov. 2017 16 241 263 10.1038/nrd.2016.256 28280262
Pfister, S. X. & Ashworth, A. Marked for death: Targeting epigenetic changes in cancer. Nat. Rev. Drug Discov. 16, 241–263 (2017).28280262 10.1038/nrd.2016.256
123. Wang Y Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer Mol. Cancer 2023 22 81 10.1186/s12943-023-01780-4 37161388
Wang, Y. et al. Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer. Mol. Cancer 22, 81 (2023).37161388 10.1186/s12943-023-01780-4
124. Lin Z N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis Mol. Ther. J. Am. Soc. Gene Ther. 2023 31 517 534 10.1016/j.ymthe.2022.10.012
Lin, Z. et al. N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis. Mol. Ther. J. Am. Soc. Gene Ther. 31, 517–534 (2023).10.1016/j.ymthe.2022.10.012
125. Thomalla D Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies Blood 2022 140 2113 2126 10.1182/blood.2021014304 35704690
Thomalla, D. et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood 140, 2113–2126 (2022).35704690 10.1182/blood.2021014304
126. Wang L METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma Cancer Lett. 2023 559 216122 10.1016/j.canlet.2023.216122 36898427
Wang, L. et al. METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett. 559, 216122 (2023).36898427 10.1016/j.canlet.2023.216122
127. Buenrostro JD Giresi PG Zaba LC Chang HY Greenleaf WJ Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position Nat. Methods 2013 10 1213 1218 10.1038/nmeth.2688 24097267
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213–1218 (2013).24097267 10.1038/nmeth.2688
128. Ohguchi H Lysine Demethylase 5A is required for MYC driven transcription in multiple myeloma Blood Cancer Discov. 2021 2 370 387 10.1158/2643-3230.BCD-20-0108 34258103
Ohguchi, H. et al. Lysine Demethylase 5A is required for MYC driven transcription in multiple myeloma. Blood Cancer Discov. 2, 370–387 (2021).34258103 10.1158/2643-3230.BCD-20-0108
129. Peng D Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor Cell Death Discov. 2021 7 9 10.1038/s41420-020-00396-7 33436536
Peng, D. et al. Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor. Cell Death Discov. 7, 9 (2021).33436536 10.1038/s41420-020-00396-7
130. Teng Y-C Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis Cancer Res 2013 73 4711 4721 10.1158/0008-5472.CAN-12-3165 23722541
Teng, Y.-C. et al. Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res 73, 4711–4721 (2013).23722541 10.1158/0008-5472.CAN-12-3165
131. Yang G-J The emerging role of KDM5A in human cancer J. Hematol. Oncol. J. Hematol. Oncol. 2021 14 30 10.1186/s13045-021-01041-1 33596982
Yang, G.-J. et al. The emerging role of KDM5A in human cancer. J. Hematol. Oncol. J. Hematol. Oncol. 14, 30 (2021).33596982 10.1186/s13045-021-01041-1
132. Liang K-H Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells Cancer Lett. 2018 433 165 175 10.1016/j.canlet.2018.06.040 29981429
Liang, K.-H. et al. Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Lett. 433, 165–175 (2018).29981429 10.1016/j.canlet.2018.06.040
133. Simón-Carrasco L Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma Genes Dev. 2017 31 1456 1468 10.1101/gad.300244.117 28827401
Simón-Carrasco, L. et al. Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes Dev. 31, 1456–1468 (2017).28827401 10.1101/gad.300244.117
134. Huang S Genome-wide CRISPR/Cas9 library screening identified that DUSP4 deficiency induces Lenvatinib resistance in Hepatocellular carcinoma Int. J. Biol. Sci. 2022 18 4357 4371 10.7150/ijbs.69969 35864956
Huang, S. et al. Genome-wide CRISPR/Cas9 library screening identified that DUSP4 deficiency induces Lenvatinib resistance in Hepatocellular carcinoma. Int. J. Biol. Sci. 18, 4357–4371 (2022).35864956 10.7150/ijbs.69969
135. Gupta A Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma Br. J. Cancer 2020 122 506 516 10.1038/s41416-019-0673-5 31839677
Gupta, A. et al. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. Br. J. Cancer 122, 506–516 (2020).31839677 10.1038/s41416-019-0673-5
136. Chesnokov MS Yadav A Chefetz I Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer Int. J. Mol. Sci. 2022 23 13365 10.3390/ijms232113365 36362153
Chesnokov, M. S., Yadav, A. & Chefetz, I. Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer. Int. J. Mol. Sci. 23, 13365 (2022).36362153 10.3390/ijms232113365
137. Wang J PHLDA1 promotes glioblastoma cell growth via sustaining the activation state of Ras Cell. Mol. Life Sci. CMLS 2022 79 520 10.1007/s00018-022-04538-1 36107262
Wang, J. et al. PHLDA1 promotes glioblastoma cell growth via sustaining the activation state of Ras. Cell. Mol. Life Sci. CMLS 79, 520 (2022).36107262 10.1007/s00018-022-04538-1
138. Kubota Y Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer Nat. Commun. 2022 13 4063 10.1038/s41467-022-31690-w 35831322
Kubota, Y. et al. Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer. Nat. Commun. 13, 4063 (2022).35831322 10.1038/s41467-022-31690-w
139. Lee H-Y Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells J. Natl Cancer Inst. 2004 96 1536 1548 10.1093/jnci/djh286 15494604
Lee, H.-Y. et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J. Natl Cancer Inst. 96, 1536–1548 (2004).15494604 10.1093/jnci/djh286
140. Ng EFY Kaida A Nojima H Miura M Roles of IGFBP-3 in cell migration and growth in an endophytic tongue squamous cell carcinoma cell line Sci. Rep. 2022 12 11503 10.1038/s41598-022-15737-y 35798794
Ng, E. F. Y., Kaida, A., Nojima, H. & Miura, M. Roles of IGFBP-3 in cell migration and growth in an endophytic tongue squamous cell carcinoma cell line. Sci. Rep. 12, 11503 (2022).35798794 10.1038/s41598-022-15737-y
141. Maddodi N Bhat KMR Devi S Zhang S-C Setaluri V Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1 J. Biol. Chem. 2010 285 242 254 10.1074/jbc.M109.068668 19880519
Maddodi, N., Bhat, K. M. R., Devi, S., Zhang, S.-C. & Setaluri, V. Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1. J. Biol. Chem. 285, 242–254 (2010).19880519 10.1074/jbc.M109.068668
142. Freytag J PAI-1 mediates the TGF-beta1+EGF-induced ‘scatter’ response in transformed human keratinocytes J. Invest. Dermatol. 2010 130 2179 2190 10.1038/jid.2010.106 20428185
Freytag, J. et al. PAI-1 mediates the TGF-beta1+EGF-induced ‘scatter’ response in transformed human keratinocytes. J. Invest. Dermatol. 130, 2179–2190 (2010).20428185 10.1038/jid.2010.106
143. Wang Q Yang S Wang K Sun S-Y MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer J. Hematol. Oncol. J. Hematol. Oncol. 2019 12 63 10.1186/s13045-019-0759-9 31227004
Wang, Q., Yang, S., Wang, K. & Sun, S.-Y. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J. Hematol. Oncol. J. Hematol. Oncol. 12, 63 (2019).31227004 10.1186/s13045-019-0759-9
144. Noronha A AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer Cancer Discov. 2022 12 2666 2683 10.1158/2159-8290.CD-22-0111 35895872
Noronha, A. et al. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discov. 12, 2666–2683 (2022).35895872 10.1158/2159-8290.CD-22-0111
145. Namba K Activation of AXL as a preclinical acquired resistance mechanism against Osimertinib treatment in EGFR-mutant non-small cell lung cancer cells Mol. Cancer Res. MCR 2019 17 499 507 10.1158/1541-7786.MCR-18-0628 30463991
Namba, K. et al. Activation of AXL as a preclinical acquired resistance mechanism against Osimertinib treatment in EGFR-mutant non-small cell lung cancer cells. Mol. Cancer Res. MCR 17, 499–507 (2019).30463991 10.1158/1541-7786.MCR-18-0628
146. Murakami Y AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer Sci. Rep. 2022 12 8983 10.1038/s41598-022-12995-8 35643725
Murakami, Y. et al. AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer. Sci. Rep. 12, 8983 (2022).35643725 10.1038/s41598-022-12995-8
147. Zhang Z Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nat. Genet. 2012 44 852 860 10.1038/ng.2330 22751098
Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852–860 (2012).22751098 10.1038/ng.2330
148. Rho JK MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation Cancer Res. 2014 74 253 262 10.1158/0008-5472.CAN-13-1103 24165158
Rho, J. K. et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 74, 253–262 (2014).24165158 10.1158/0008-5472.CAN-13-1103
149. Wang T-H Integrated Omics analysis of non-small-cell lung cancer cells harboring the EGFR C797S mutation reveals the potential of AXL as a novel therapeutic target in TKI-resistant lung cancer Cancers 2020 13 111 10.3390/cancers13010111 33396393
Wang, T.-H. et al. Integrated Omics analysis of non-small-cell lung cancer cells harboring the EGFR C797S mutation reveals the potential of AXL as a novel therapeutic target in TKI-resistant lung cancer. Cancers 13, 111 (2020).33396393 10.3390/cancers13010111
150. Suda K Epithelial to Mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to Erlotinib J. Thorac. Oncol. 2011 6 1152 1161 10.1097/JTO.0b013e318216ee52 21597390
Suda, K. et al. Epithelial to Mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to Erlotinib. J. Thorac. Oncol. 6, 1152–1161 (2011).21597390 10.1097/JTO.0b013e318216ee52
151. Wang J Wang S Sun J Qiu L Expression of c-MET, EGFR and HER-2 in gastric adenocarcinoma tissue and its relationship with clinicopathological characteristics Am. J. Transl. Res. 2021 13 10856 10862 34650766
Wang, J., Wang, S., Sun, J. & Qiu, L. Expression of c-MET, EGFR and HER-2 in gastric adenocarcinoma tissue and its relationship with clinicopathological characteristics. Am. J. Transl. Res. 13, 10856–10862 (2021).34650766
152. Yıldız Y Sokmensuer C Yalcin S Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors Onco Targets Ther. 2016 9 5809 5817 10.2147/OTT.S107946 27703380
Yıldız, Y., Sokmensuer, C. & Yalcin, S. Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors. Onco Targets Ther. 9, 5809–5817 (2016).27703380 10.2147/OTT.S107946
153. Dhanasekaran R The MYC oncogene - the grand orchestrator of cancer growth and immune evasion Nat. Rev. Clin. Oncol. 2022 19 23 36 10.1038/s41571-021-00549-2 34508258
Dhanasekaran, R. et al. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 19, 23–36 (2022).34508258 10.1038/s41571-021-00549-2
154. Ullah R Yin Q Snell AH Wan L RAF-MEK-ERK pathway in cancer evolution and treatment Semin. Cancer Biol. 2022 85 123 154 10.1016/j.semcancer.2021.05.010 33992782
Ullah, R., Yin, Q., Snell, A. H. & Wan, L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin. Cancer Biol. 85, 123–154 (2022).33992782 10.1016/j.semcancer.2021.05.010
155. Suchors C Kim J Canonical Hedgehog pathway and noncanonical GLI transcription factor activation in cancer Cells 2022 11 2523 10.3390/cells11162523 36010600
Suchors, C. & Kim, J. Canonical Hedgehog pathway and noncanonical GLI transcription factor activation in cancer. Cells 11, 2523 (2022).36010600 10.3390/cells11162523
156. Calses PC Crawford JJ Lill JR Dey A Hippo pathway in cancer: aberrant regulation and therapeutic opportunities Trends Cancer 2019 5 297 307 10.1016/j.trecan.2019.04.001 31174842
Calses, P. C., Crawford, J. J., Lill, J. R. & Dey, A. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer 5, 297–307 (2019).31174842 10.1016/j.trecan.2019.04.001
157. Zhou B Notch signaling pathway: architecture, disease, and therapeutics Signal Transduct. Target. Ther. 2022 7 95 10.1038/s41392-022-00934-y 35332121
Zhou, B. et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct. Target. Ther. 7, 95 (2022).35332121 10.1038/s41392-022-00934-y
158. Deng S Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance Nat. Cancer 2022 3 1071 1087 10.1038/s43018-022-00431-9 36065066
Deng, S. et al. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat. Cancer 3, 1071–1087 (2022).36065066 10.1038/s43018-022-00431-9
159. Tian Y MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer Adv. Sci. Weinh. Baden.-Wurtt. Ger. 2023 10 e2204819
Tian, Y. et al. MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer. Adv. Sci. Weinh. Baden.-Wurtt. Ger. 10, e2204819 (2023).
160. Xu J-C NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway Int. J. Biol. Sci. 2021 17 259 270 10.7150/ijbs.53795 33390848
Xu, J.-C. et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway. Int. J. Biol. Sci. 17, 259–270 (2021).33390848 10.7150/ijbs.53795
161. Lin X KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother. 2023 66 100908
Lin, X. et al. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner. Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother. 66, 100908 (2023).
162. Sun X NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway Cancer Sci. 2024 115 412 426 10.1111/cas.16040 38115797
Sun, X. et al. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway. Cancer Sci. 115, 412–426 (2024).38115797 10.1111/cas.16040
163. Dutta PR Maity A Cellular responses to EGFR inhibitors and their relevance to cancer therapy Cancer Lett. 2007 254 165 177 10.1016/j.canlet.2007.02.006 17367921
Dutta, P. R. & Maity, A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 254, 165–177 (2007).17367921 10.1016/j.canlet.2007.02.006
164. Fresno Vara JA PI3K/Akt signalling pathway and cancer Cancer Treat. Rev. 2004 30 193 204 10.1016/j.ctrv.2003.07.007 15023437
Fresno Vara, J. A. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193–204 (2004).15023437 10.1016/j.ctrv.2003.07.007
165. Gremke N mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability Nat. Commun. 2020 11 4684 10.1038/s41467-020-18504-7 32943635
Gremke, N. et al. mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat. Commun. 11, 4684 (2020).32943635 10.1038/s41467-020-18504-7
166. Leon G MacDonagh L Finn SP Cuffe S Barr MP Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways Pharmacol. Ther. 2016 158 71 90 10.1016/j.pharmthera.2015.12.001 26706243
Leon, G., MacDonagh, L., Finn, S. P., Cuffe, S. & Barr, M. P. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Pharmacol. Ther. 158, 71–90 (2016).26706243 10.1016/j.pharmthera.2015.12.001
167. Narayanan S Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother. 2020 48 100663
Narayanan, S. et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother. 48, 100663 (2020).
168. Taniguchi H AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells Nat. Commun. 2019 10 259 10.1038/s41467-018-08074-0 30651547
Taniguchi, H. et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat. Commun. 10, 259 (2019).30651547 10.1038/s41467-018-08074-0
169. Shiozawa Y GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche Neoplasia N. Y. N. 2010 12 116 127 10.1593/neo.91384
Shiozawa, Y. et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia N. Y. N. 12, 116–127 (2010).10.1593/neo.91384
170. Ibar C Irvine KD Integration of Hippo-YAP Signaling with Metabolism Dev. Cell 2020 54 256 267 10.1016/j.devcel.2020.06.025 32693058
Ibar, C. & Irvine, K. D. Integration of Hippo-YAP Signaling with Metabolism. Dev. Cell 54, 256–267 (2020).32693058 10.1016/j.devcel.2020.06.025
171. Kurppa KJ Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway Cancer Cell 2020 37 104 122.e12 10.1016/j.ccell.2019.12.006 31935369
Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104–122.e12 (2020).31935369 10.1016/j.ccell.2019.12.006
172. Bossart EA SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma Breast Cancer Res. Treat. 2019 175 327 337 10.1007/s10549-019-05161-8 30798422
Bossart, E. A. et al. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Res. Treat. 175, 327–337 (2019).30798422 10.1007/s10549-019-05161-8
173. Noman MZ The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200 Oncoimmunology 2017 6 e1263412 10.1080/2162402X.2016.1263412 28197390
Noman, M. Z. et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology 6, e1263412 (2017).28197390 10.1080/2162402X.2016.1263412
174. Sun C Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma Nature 2014 508 118 122 10.1038/nature13121 24670642
Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118–122 (2014).24670642 10.1038/nature13121
175. Prahallad A Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 2012 483 100 103 10.1038/nature10868 22281684
Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012).22281684 10.1038/nature10868
176. Kopetz S Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-mutated colorectal cancer N. Engl. J. Med. 2019 381 1632 1643 10.1056/NEJMoa1908075 31566309
Kopetz, S. et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019).31566309 10.1056/NEJMoa1908075
177. Nie M Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse J. Clin. Invest. 2022 132 e160152 10.1172/JCI160152 36048538
Nie, M. et al. Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse. J. Clin. Invest. 132, e160152 (2022).36048538 10.1172/JCI160152
178. Cheng K Muscarinic receptor agonist-induced βPix binding to β-catenin promotes colon neoplasia Sci. Rep. 2023 13 16920 10.1038/s41598-023-44158-8 37805544
Cheng, K. et al. Muscarinic receptor agonist-induced βPix binding to β-catenin promotes colon neoplasia. Sci. Rep. 13, 16920 (2023).37805544 10.1038/s41598-023-44158-8
179. Farhana L Bile acid: a potential inducer of colon cancer stem cells Stem Cell Res. Ther. 2016 7 181 10.1186/s13287-016-0439-4 27908290
Farhana, L. et al. Bile acid: a potential inducer of colon cancer stem cells. Stem Cell Res. Ther. 7, 181 (2016).27908290 10.1186/s13287-016-0439-4
180. Zhan T Rindtorff N Boutros M Wnt signaling in cancer Oncogene 2017 36 1461 1473 10.1038/onc.2016.304 27617575
Zhan, T., Rindtorff, N. & Boutros, M. Wnt signaling in cancer. Oncogene 36, 1461–1473 (2017).27617575 10.1038/onc.2016.304
181. Nusse R Clevers H Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities Cell 2017 169 985 999 10.1016/j.cell.2017.05.016 28575679
Nusse, R. & Clevers, H. Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017).28575679 10.1016/j.cell.2017.05.016
182. Wei C-Y Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma J. Hematol. Oncol. J. Hematol. Oncol. 2019 12 21 10.1186/s13045-019-0711-z 30832692
Wei, C.-Y. et al. Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J. Hematol. Oncol. J. Hematol. Oncol. 12, 21 (2019).30832692 10.1186/s13045-019-0711-z
183. Legge DN BCL-3 promotes a cancer stem cell phenotype by enhancing β-catenin signalling in colorectal tumour cells Dis. Model. Mech. 2019 12 dmm037697 10.1242/dmm.037697 30792270
Legge, D. N. et al. BCL-3 promotes a cancer stem cell phenotype by enhancing β-catenin signalling in colorectal tumour cells. Dis. Model. Mech. 12, dmm037697 (2019).30792270 10.1242/dmm.037697
184. Sulaiman A Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states Mol. Oncol. 2018 12 423 440 10.1002/1878-0261.12167 29316250
Sulaiman, A. et al. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Mol. Oncol. 12, 423–440 (2018).29316250 10.1002/1878-0261.12167
185. Takahashi H Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer Cancer Sci. 2023 114 1635 1650 10.1111/cas.15674 36411521
Takahashi, H. et al. Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer. Cancer Sci. 114, 1635–1650 (2023).36411521 10.1111/cas.15674
186. Haven B Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations eLife 2016 5 e09462 10.7554/eLife.09462 26905833
Haven, B. et al. Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. eLife 5, e09462 (2016).26905833 10.7554/eLife.09462
187. Wang R Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer Nat. Commun. 2020 11 4607 10.1038/s41467-020-18442-4 32929081
Wang, R. et al. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat. Commun. 11, 4607 (2020).32929081 10.1038/s41467-020-18442-4
188. Xiao Y Yu D Tumor microenvironment as a therapeutic target in cancer Pharmacol. Ther. 2021 221 107753 10.1016/j.pharmthera.2020.107753 33259885
Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753 (2021).33259885 10.1016/j.pharmthera.2020.107753
189. Hinshaw DC Shevde LA The tumor microenvironment innately modulates cancer progression Cancer Res. 2019 79 4557 4566 10.1158/0008-5472.CAN-18-3962 31350295
Hinshaw, D. C. & Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Res. 79, 4557–4566 (2019).31350295 10.1158/0008-5472.CAN-18-3962
190. Straussman R Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 2012 487 500 504 10.1038/nature11183 22763439
Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500–504 (2012).22763439 10.1038/nature11183
191. Erin N Grahovac J Brozovic A Efferth T Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother. 2020 53 100715
Erin, N., Grahovac, J., Brozovic, A. & Efferth, T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother. 53, 100715 (2020).
192. Liu H Zhao H Sun Y Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies Semin. Cancer Biol. 2022 86 769 781 10.1016/j.semcancer.2021.11.004 34799201
Liu, H., Zhao, H. & Sun, Y. Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies. Semin. Cancer Biol. 86, 769–781 (2022).34799201 10.1016/j.semcancer.2021.11.004
193. Chen Y Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment Front. Immunol. 2023 14 1106090 10.3389/fimmu.2023.1106090 36923412
Chen, Y. et al. Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment. Front. Immunol. 14, 1106090 (2023).36923412 10.3389/fimmu.2023.1106090
194. Elyada E Cross-species single-cell analysis of pancreatic ductal Adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts Cancer Discov. 2019 9 1102 1123 10.1158/2159-8290.CD-19-0094 31197017
Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal Adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102–1123 (2019).31197017 10.1158/2159-8290.CD-19-0094
195. Hu JL CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer Mol. Cancer 2019 18 91 10.1186/s12943-019-1019-x 31064356
Hu, J. L. et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol. Cancer 18, 91 (2019).31064356 10.1186/s12943-019-1019-x
196. Linares J Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy Nat. Commun. 2023 14 746 10.1038/s41467-023-36334-1 36765091
Linares, J. et al. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Nat. Commun. 14, 746 (2023).36765091 10.1038/s41467-023-36334-1
197. Yang X m6 A-dependent modulation via IGF2BP3/MCM5/Notch axis promotes partial EMT and LUAD metastasis Adv. Sci. Weinh. Baden.-Wurtt. Ger. 2023 10 e2206744
Yang, X. et al. m6 A-dependent modulation via IGF2BP3/MCM5/Notch axis promotes partial EMT and LUAD metastasis. Adv. Sci. Weinh. Baden.-Wurtt. Ger. 10, e2206744 (2023).
198. Hu X-T HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer J. Exp. Clin. Cancer Res. CR 2020 39 270 10.1186/s13046-020-01783-9 33267897
Hu, X.-T. et al. HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer. J. Exp. Clin. Cancer Res. CR 39, 270 (2020).33267897 10.1186/s13046-020-01783-9
199. Deshmukh AP Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing Proc. Natl Acad. Sci. USA 2021 118 e2102050118 10.1073/pnas.2102050118 33941680
Deshmukh, A. P. et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc. Natl Acad. Sci. USA 118, e2102050118 (2021).33941680 10.1073/pnas.2102050118
200. Cho I-H Suppression of LPS-induced epithelial-mesenchymal transition by aqueous extracts of Prunella vulgaris through inhibition of the NF-κB/Snail signaling pathway and regulation of EMT-related protein expression Oncol. Rep. 2015 34 2445 2450 10.3892/or.2015.4218 26324883
Cho, I.-H. et al. Suppression of LPS-induced epithelial-mesenchymal transition by aqueous extracts of Prunella vulgaris through inhibition of the NF-κB/Snail signaling pathway and regulation of EMT-related protein expression. Oncol. Rep. 34, 2445–2450 (2015).26324883 10.3892/or.2015.4218
201. Viswanathan VS Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway Nature 2017 547 453 457 10.1038/nature23007 28678785
Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453–457 (2017).28678785 10.1038/nature23007
202. Krebs AM The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer Nat. Cell Biol. 2017 19 518 529 10.1038/ncb3513 28414315
Krebs, A. M. et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell Biol. 19, 518–529 (2017).28414315 10.1038/ncb3513
203. Liu M Zinc-dependent regulation of ZEB1 and YAP1 coactivation promotes epithelial-mesenchymal transition plasticity and metastasis in pancreatic cancer Gastroenterology 2021 160 1771 1783.e1 10.1053/j.gastro.2020.12.077 33421513
Liu, M. et al. Zinc-dependent regulation of ZEB1 and YAP1 coactivation promotes epithelial-mesenchymal transition plasticity and metastasis in pancreatic cancer. Gastroenterology 160, 1771–1783.e1 (2021).33421513 10.1053/j.gastro.2020.12.077
204. Peng D Fu M Wang M Wei Y Wei X Targeting TGF-β signal transduction for fibrosis and cancer therapy Mol. Cancer 2022 21 104 10.1186/s12943-022-01569-x 35461253
Peng, D., Fu, M., Wang, M., Wei, Y. & Wei, X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol. Cancer 21, 104 (2022).35461253 10.1186/s12943-022-01569-x
205. Funaba M Zimmerman CM Mathews LS Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase J. Biol. Chem. 2002 277 41361 41368 10.1074/jbc.M204597200 12193595
Funaba, M., Zimmerman, C. M. & Mathews, L. S. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J. Biol. Chem. 277, 41361–41368 (2002).12193595 10.1074/jbc.M204597200
206. Scherer A Graff JM Calmodulin differentially modulates Smad1 and Smad2 signaling J. Biol. Chem. 2000 275 41430 41438 10.1074/jbc.M005727200 11007779
Scherer, A. & Graff, J. M. Calmodulin differentially modulates Smad1 and Smad2 signaling. J. Biol. Chem. 275, 41430–41438 (2000).11007779 10.1074/jbc.M005727200
207. Hsu PP Sabatini DM Cancer cell metabolism: Warburg and beyond Cell 2008 134 703 707 10.1016/j.cell.2008.08.021 18775299
Hsu, P. P. & Sabatini, D. M. Cancer cell metabolism: Warburg and beyond. Cell 134, 703–707 (2008).18775299 10.1016/j.cell.2008.08.021
208. Ganapathy-Kanniappan S Geschwind J-FH Tumor glycolysis as a target for cancer therapy: Progress and prospects Mol. Cancer 2013 12 152 10.1186/1476-4598-12-152 24298908
Ganapathy-Kanniappan, S. & Geschwind, J.-F. H. Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol. Cancer 12, 152 (2013).24298908 10.1186/1476-4598-12-152
209. Brunner JS Finley LWS SnapShot: Cancer metabolism Mol. Cell 2021 81 3878 3878.e1 10.1016/j.molcel.2021.06.021 34547243
Brunner, J. S. & Finley, L. W. S. SnapShot: Cancer metabolism. Mol. Cell 81, 3878–3878.e1 (2021).34547243 10.1016/j.molcel.2021.06.021
210. Granit Mizrahi A Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells Front. Cell Dev. Biol. 2023 11 1217149 10.3389/fcell.2023.1217149 37954205
Granit Mizrahi, A. et al. Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells. Front. Cell Dev. Biol. 11, 1217149 (2023).37954205 10.3389/fcell.2023.1217149
211. Lee K-M MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation Cell Metab. 2017 26 633 647.e7 10.1016/j.cmet.2017.09.009 28978427
Lee, K.-M. et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 26, 633–647.e7 (2017).28978427 10.1016/j.cmet.2017.09.009
212. Liu X Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo Redox Biol. 2020 36 101652 10.1016/j.redox.2020.101652 32750669
Liu, X. et al. Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo. Redox Biol. 36, 101652 (2020).32750669 10.1016/j.redox.2020.101652
213. Lumibao JC CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance Int. J. Oncol. 2023 63 117 10.3892/ijo.2023.5565 37654190
Lumibao, J. C. et al. CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance. Int. J. Oncol. 63, 117 (2023).37654190 10.3892/ijo.2023.5565
214. Sharon D Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response Sci. Transl. Med. 2019 11 eaax2863 10.1126/scitranslmed.aax2863 31666400
Sharon, D. et al. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci. Transl. Med. 11, eaax2863 (2019).31666400 10.1126/scitranslmed.aax2863
215. Stuani L Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia J. Exp. Med. 2021 218 e20200924 10.1084/jem.20200924 33760042
Stuani, L. et al. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J. Exp. Med. 218, e20200924 (2021).33760042 10.1084/jem.20200924
216. Sies H Oxidative eustress: On constant alert for redox homeostasis Redox Biol. 2021 41 101867 10.1016/j.redox.2021.101867 33657525
Sies, H. Oxidative eustress: On constant alert for redox homeostasis. Redox Biol. 41, 101867 (2021).33657525 10.1016/j.redox.2021.101867
217. Sies H Oxidative stress: a concept in redox biology and medicine Redox Biol. 2015 4 180 183 10.1016/j.redox.2015.01.002 25588755
Sies, H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 4, 180–183 (2015).25588755 10.1016/j.redox.2015.01.002
218. Diaz-Vivancos P de Simone A Kiddle G Foyer CH Glutathione–linking cell proliferation to oxidative stress Free Radic. Biol. Med. 2015 89 1154 1164 10.1016/j.freeradbiomed.2015.09.023 26546102
Diaz-Vivancos, P., de Simone, A., Kiddle, G. & Foyer, C. H. Glutathione–linking cell proliferation to oxidative stress. Free Radic. Biol. Med. 89, 1154–1164 (2015).26546102 10.1016/j.freeradbiomed.2015.09.023
219. Matsui R Redox regulation via Glutaredoxin-1 and Protein S-Glutathionylation Antioxid. Redox Signal. 2020 32 677 700 10.1089/ars.2019.7963 31813265
Matsui, R. et al. Redox regulation via Glutaredoxin-1 and Protein S-Glutathionylation. Antioxid. Redox Signal. 32, 677–700 (2020).31813265 10.1089/ars.2019.7963
220. Sies H Glutathione and its role in cellular functions Free Radic. Biol. Med. 1999 27 916 921 10.1016/S0891-5849(99)00177-X 10569624
Sies, H. Glutathione and its role in cellular functions. Free Radic. Biol. Med. 27, 916–921 (1999).10569624 10.1016/S0891-5849(99)00177-X
221. Sinha M Mardinoglu A Ghose J Singh K Editorial: Redox homeostasis and cancer Oxid. Med. Cell. Longev. 2020 2020 5487381 10.1155/2020/5487381 33488925
Sinha, M., Mardinoglu, A., Ghose, J. & Singh, K. Editorial: Redox homeostasis and cancer. Oxid. Med. Cell. Longev. 2020, 5487381 (2020).33488925 10.1155/2020/5487381
222. Liu J Redox imbalance triggered intratumoral cascade reaction for tumor ‘turn on’ imaging and synergistic therapy Small Weinh. Bergstr. Ger. 2023 19 e2206272 10.1002/smll.202206272
Liu, J. et al. Redox imbalance triggered intratumoral cascade reaction for tumor ‘turn on’ imaging and synergistic therapy. Small Weinh. Bergstr. Ger. 19, e2206272 (2023).10.1002/smll.202206272
223. DeBerardinis RJ Chandel NS Fundamentals of cancer metabolism Sci. Adv. 2016 2 e1600200 10.1126/sciadv.1600200 27386546
DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).27386546 10.1126/sciadv.1600200
224. Dai X Wang D Zhang J Programmed cell death, redox imbalance, and cancer therapeutics Apoptosis Int. J. Program. Cell Death 2021 26 385 414 10.1007/s10495-021-01682-0
Dai, X., Wang, D. & Zhang, J. Programmed cell death, redox imbalance, and cancer therapeutics. Apoptosis Int. J. Program. Cell Death 26, 385–414 (2021).10.1007/s10495-021-01682-0
225. Jung E Tumor-targeted redox-regulating and antiangiogenic phototherapeutics nanoassemblies for self-boosting phototherapy Biomaterials 2023 298 122127 10.1016/j.biomaterials.2023.122127 37086554
Jung, E. et al. Tumor-targeted redox-regulating and antiangiogenic phototherapeutics nanoassemblies for self-boosting phototherapy. Biomaterials 298, 122127 (2023).37086554 10.1016/j.biomaterials.2023.122127
226. Wang Y Tumor-selective biodegradation-regulated Photothermal H2 S Donor for Redox Dyshomeostasis- and Glycolysis disorder-enhanced Theranostics Small Weinh. Bergstr. Ger. 2022 18 e2106168 10.1002/smll.202106168
Wang, Y. et al. Tumor-selective biodegradation-regulated Photothermal H2 S Donor for Redox Dyshomeostasis- and Glycolysis disorder-enhanced Theranostics. Small Weinh. Bergstr. Ger. 18, e2106168 (2022).10.1002/smll.202106168
227. Zhao F Redox Homeostasis disruptors based on metal-phenolic network nanoparticles for chemo/chemodynamic synergistic tumor therapy through activating apoptosis and cuproptosis Adv. Healthc. Mater. 2023 12 e2301346 10.1002/adhm.202301346 37369362
Zhao, F. et al. Redox Homeostasis disruptors based on metal-phenolic network nanoparticles for chemo/chemodynamic synergistic tumor therapy through activating apoptosis and cuproptosis. Adv. Healthc. Mater. 12, e2301346 (2023).37369362 10.1002/adhm.202301346
228. Chen X Li J Kang R Klionsky DJ Tang D Ferroptosis: machinery and regulation Autophagy 2021 17 2054 2081 10.1080/15548627.2020.1810918 32804006
Chen, X., Li, J., Kang, R., Klionsky, D. J. & Tang, D. Ferroptosis: machinery and regulation. Autophagy 17, 2054–2081 (2021).32804006 10.1080/15548627.2020.1810918
229. Lennicke C Cochemé HM Redox metabolism: ROS as specific molecular regulators of cell signaling and function Mol. Cell 2021 81 3691 3707 10.1016/j.molcel.2021.08.018 34547234
Lennicke, C. & Cochemé, H. M. Redox metabolism: ROS as specific molecular regulators of cell signaling and function. Mol. Cell 81, 3691–3707 (2021).34547234 10.1016/j.molcel.2021.08.018
230. Kang KA Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation Cell Death Dis. 2014 5 e1183 10.1038/cddis.2014.149 24743738
Kang, K. A. et al. Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis. 5, e1183 (2014).24743738 10.1038/cddis.2014.149
231. Yang WS Regulation of ferroptotic cancer cell death by GPX4 Cell 2014 156 317 331 10.1016/j.cell.2013.12.010 24439385
Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).24439385 10.1016/j.cell.2013.12.010
232. Seiler A Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death Cell Metab. 2008 8 237 248 10.1016/j.cmet.2008.07.005 18762024
Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8, 237–248 (2008).18762024 10.1016/j.cmet.2008.07.005
233. Ingold I Selenium utilization by GPX4 is required to prevent hydroperoxide-induced Ferroptosis Cell 2018 172 409 422.e21 10.1016/j.cell.2017.11.048 29290465
Ingold, I. et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced Ferroptosis. Cell 172, 409–422.e21 (2018).29290465 10.1016/j.cell.2017.11.048
234. Rodriguez R Schreiber SL Conrad M Persister cancer cells: Iron addiction and vulnerability to ferroptosis Mol. Cell 2022 82 728 740 10.1016/j.molcel.2021.12.001 34965379
Rodriguez, R., Schreiber, S. L. & Conrad, M. Persister cancer cells: Iron addiction and vulnerability to ferroptosis. Mol. Cell 82, 728–740 (2022).34965379 10.1016/j.molcel.2021.12.001
235. Chaudhary N Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer Int. J. Cancer 2021 149 1495 1511 10.1002/ijc.33711 34146401
Chaudhary, N. et al. Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer. Int. J. Cancer 149, 1495–1511 (2021).34146401 10.1002/ijc.33711
236. Hata AN Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition Nat. Med. 2016 22 262 269 10.1038/nm.4040 26828195
Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016).26828195 10.1038/nm.4040
237. Fan W MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents Cancer Res. 2011 71 4494 4505 10.1158/0008-5472.CAN-10-2668 21555370
Fan, W. et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 71, 4494–4505 (2011).21555370 10.1158/0008-5472.CAN-10-2668
238. Kalkavan H Sublethal cytochrome c release generates drug-tolerant persister cells Cell 2022 185 3356 3374.e22 10.1016/j.cell.2022.07.025 36055199
Kalkavan, H. et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell 185, 3356–3374.e22 (2022).36055199 10.1016/j.cell.2022.07.025
239. Tanei T Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers Clin. Cancer Res. J. Am. Assoc. Cancer Res. 2009 15 4234 4241 10.1158/1078-0432.CCR-08-1479
Tanei, T. et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 15, 4234–4241 (2009).10.1158/1078-0432.CCR-08-1479
240. Singh S Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress Free Radic. Biol. Med. 2013 56 89 101 10.1016/j.freeradbiomed.2012.11.010 23195683
Singh, S. et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic. Biol. Med. 56, 89–101 (2013).23195683 10.1016/j.freeradbiomed.2012.11.010
241. Barrera G Oxidative stress and lipid peroxidation products in cancer progression and therapy ISRN Oncol. 2012 2012 137289 23119185
Barrera, G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012, 137289 (2012).23119185
242. Bock FJ Tait SWG Mitochondria as multifaceted regulators of cell death Nat. Rev. Mol. Cell Biol. 2020 21 85 100 10.1038/s41580-019-0173-8 31636403
Bock, F. J. & Tait, S. W. G. Mitochondria as multifaceted regulators of cell death. Nat. Rev. Mol. Cell Biol. 21, 85–100 (2020).31636403 10.1038/s41580-019-0173-8
243. Green DR The Mitochondrial Pathway of Apoptosis: Part I: MOMP and Beyond Cold Spring Harb. Perspect. Biol. 2022 14 a041038 10.1101/cshperspect.a041038 35623793
Green, D. R. The Mitochondrial Pathway of Apoptosis: Part I: MOMP and Beyond. Cold Spring Harb. Perspect. Biol. 14, a041038 (2022).35623793 10.1101/cshperspect.a041038
244. Oberst, A., Ichim, G. & Tait, S. W. G. Mitochondrial Permeabilization: From Lethality to Vitality. in Mitochondria and Cell Death (ed. Hockenbery, D. M.) 213–226 (Springer New York, New York, NY, 2016). 10.1007/978-1-4939-3612-0_11.
245. Berthenet K Failed apoptosis enhances melanoma cancer cell aggressiveness Cell Rep. 2020 31 107731 10.1016/j.celrep.2020.107731 32521256
Berthenet, K. et al. Failed apoptosis enhances melanoma cancer cell aggressiveness. Cell Rep. 31, 107731 (2020).32521256 10.1016/j.celrep.2020.107731
246. Ichim G Tait SWG A fate worse than death: apoptosis as an oncogenic process Nat. Rev. Cancer 2016 16 539 548 10.1038/nrc.2016.58 27364482
Ichim, G. & Tait, S. W. G. A fate worse than death: apoptosis as an oncogenic process. Nat. Rev. Cancer 16, 539–548 (2016).27364482 10.1038/nrc.2016.58
247. Halbrook CJ Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells Nat. Cancer 2022 3 1386 1403 10.1038/s43018-022-00463-1 36411320
Halbrook, C. J. et al. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Nat. Cancer 3, 1386–1403 (2022).36411320 10.1038/s43018-022-00463-1
248. Verginadis II A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression Nat. Cell Biol. 2022 24 940 953 10.1038/s41556-022-00918-8 35654839
Verginadis, I. I. et al. A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nat. Cell Biol. 24, 940–953 (2022).35654839 10.1038/s41556-022-00918-8
249. Fattahi S Amjadi-Moheb F Tabaripour R Ashrafi GH Akhavan-Niaki H PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond Life Sci. 2020 262 118513 10.1016/j.lfs.2020.118513 33011222
Fattahi, S., Amjadi-Moheb, F., Tabaripour, R., Ashrafi, G. H. & Akhavan-Niaki, H. PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond. Life Sci. 262, 118513 (2020).33011222 10.1016/j.lfs.2020.118513
250. Jiao Z-Y Type 3 muscarinic acetylcholine receptor stimulation is a determinant of endothelial barrier function and adherens junctions integrity: role of protein-tyrosine phosphatase 1B BMB Rep. 2014 47 552 557 10.5483/BMBRep.2014.47.10.216 24393526
Jiao, Z.-Y. et al. Type 3 muscarinic acetylcholine receptor stimulation is a determinant of endothelial barrier function and adherens junctions integrity: role of protein-tyrosine phosphatase 1B. BMB Rep. 47, 552–557 (2014).24393526 10.5483/BMBRep.2014.47.10.216
251. Li Y Wu Q Lv J Gu J A comprehensive pan-cancer analysis of CDH5 in immunological response Front. Immunol. 2023 14 1239875 10.3389/fimmu.2023.1239875 37809080
Li, Y., Wu, Q., Lv, J. & Gu, J. A comprehensive pan-cancer analysis of CDH5 in immunological response. Front. Immunol. 14, 1239875 (2023).37809080 10.3389/fimmu.2023.1239875
252. Puig I TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence J. Clin. Invest. 2018 128 3887 3905 10.1172/JCI96393 29944140
Puig, I. et al. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J. Clin. Invest. 128, 3887–3905 (2018).29944140 10.1172/JCI96393
253. Zhang Z Inhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy EMBO Mol. Med. 2022 14 e14903 10.15252/emmm.202114903 35023619
Zhang, Z. et al. Inhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy. EMBO Mol. Med. 14, e14903 (2022).35023619 10.15252/emmm.202114903
254. Delbridge ARD Grabow S Strasser A Vaux DL Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies Nat. Rev. Cancer 2016 16 99 109 10.1038/nrc.2015.17 26822577
Delbridge, A. R. D., Grabow, S., Strasser, A. & Vaux, D. L. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 16, 99–109 (2016).26822577 10.1038/nrc.2015.17
255. Chen X Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment Cancer Discov. 2019 9 890 909 10.1158/2159-8290.CD-19-0117 31048321
Chen, X. et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment. Cancer Discov. 9, 890–909 (2019).31048321 10.1158/2159-8290.CD-19-0117
256. Liang Y Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies Clin. Cancer Res. J. Am. Assoc. Cancer Res. 2021 27 2340 2351 10.1158/1078-0432.CCR-20-3260
Liang, Y. et al. Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 27, 2340–2351 (2021).10.1158/1078-0432.CCR-20-3260
257. Lu Y Bian D Zhang X Zhang H Zhu Z Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer Mol. Med. Rep. 2021 23 48 33200796
Lu, Y., Bian, D., Zhang, X., Zhang, H. & Zhu, Z. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer. Mol. Med. Rep. 23, 48 (2021).33200796
258. Mukherjee N Combining a GSI and BCL-2 inhibitor to overcome melanoma’s resistance to current treatments Oncotarget 2016 7 84594 84607 10.18632/oncotarget.13141 27829238
Mukherjee, N. et al. Combining a GSI and BCL-2 inhibitor to overcome melanoma’s resistance to current treatments. Oncotarget 7, 84594–84607 (2016).27829238 10.18632/oncotarget.13141
259. Tse C ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 2008 68 3421 3428 10.1158/0008-5472.CAN-07-5836 18451170
Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68, 3421–3428 (2008).18451170 10.1158/0008-5472.CAN-07-5836
260. Souers AJ ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat. Med. 2013 19 202 208 10.1038/nm.3048 23291630
Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).23291630 10.1038/nm.3048
261. AbbVie. A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2). https://clinicaltrials.gov/study/NCT04468984 (2024).
262. AbbVie. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1). https://clinicaltrials.gov/study/NCT04472598 (2024).
263. National Cancer Institute (NCI). An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors. https://clinicaltrials.gov/study/NCT02079740 (2024).
264. City of Hope Medical Center. A Phase Ib Open Label Study of Navitoclax in Combination With Venetoclax + Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax. https://clinicaltrials.gov/study/NCT05222984 (2024).
265. AbbVie. Expanded Access to Navitoclax. https://clinicaltrials.gov/study/NCT03592576 (2024).
266. Skrott Z Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 Nature 2017 552 194 199 10.1038/nature25016 29211715
Skrott, Z. et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 552, 194–199 (2017).29211715 10.1038/nature25016
267. Luo H Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine Chin. Med. 2019 14 48 10.1186/s13020-019-0270-9 31719837
Luo, H. et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin. Med. 14, 48 (2019).31719837 10.1186/s13020-019-0270-9
268. Zou Y The triangular relationship between traditional Chinese medicines, intestinal flora, and colorectal cancer Med. Res. Rev. 2024 44 539 567 10.1002/med.21989 37661373
Zou, Y. et al. The triangular relationship between traditional Chinese medicines, intestinal flora, and colorectal cancer. Med. Res. Rev. 44, 539–567 (2024).37661373 10.1002/med.21989
269. Yu S-X A novel diagnostic and therapeutic strategy for cancer patients by integrating Chinese Medicine Syndrome differentiation and precision medicine Chin. J. Integr. Med. 2022 28 867 871 10.1007/s11655-022-3671-z 35508859
Yu, S.-X. et al. A novel diagnostic and therapeutic strategy for cancer patients by integrating Chinese Medicine Syndrome differentiation and precision medicine. Chin. J. Integr. Med. 28, 867–871 (2022).35508859 10.1007/s11655-022-3671-z
270. Sui X Combination of traditional Chinese medicine and epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of non-small cell lung cancer: A systematic review and meta-analysis Med. (Baltim.) 2020 99 e20683 10.1097/MD.0000000000020683
Sui, X. et al. Combination of traditional Chinese medicine and epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Med. (Baltim.) 99, e20683 (2020).10.1097/MD.0000000000020683
271. Wang K-J Emodin Induced Necroptosis and inhibited glycolysis in the renal cancer cells by enhancing ROS Oxid. Med. Cell. Longev. 2021 2021 8840590 10.1155/2021/8840590 33532038
Wang, K.-J. et al. Emodin Induced Necroptosis and inhibited glycolysis in the renal cancer cells by enhancing ROS. Oxid. Med. Cell. Longev. 2021, 8840590 (2021).33532038 10.1155/2021/8840590
272. van der Zijden, C. J. et al. Adjuvant therapy for patients with a tumor-positive resection margin after neoadjuvant Chemoradiotherapy and Esophagectomy. Ann. Surg. Oncol. 10.1245/s10434-024-14912-x (2024).
273. Xue K Huang X Zhao P Zhang Y Tian B Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer following neoadjuvant therapy: a systematic review and meta-analysis Int. J. Surg. Lond. Engl. 2023 109 4309 4321 10.1097/JS9.0000000000000742
Xue, K., Huang, X., Zhao, P., Zhang, Y. & Tian, B. Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer following neoadjuvant therapy: a systematic review and meta-analysis. Int. J. Surg. Lond. Engl. 109, 4309–4321 (2023).10.1097/JS9.0000000000000742
274. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Lancet Oncol. 2018 19 27 39 10.1016/S1470-2045(17)30777-5 29242041
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 19, 27–39 (2018).29242041 10.1016/S1470-2045(17)30777-5
275. Pullarkat VA Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma Cancer Discov. 2021 11 1440 1453 10.1158/2159-8290.CD-20-1465 33593877
Pullarkat, V. A. et al. Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 11, 1440–1453 (2021).33593877 10.1158/2159-8290.CD-20-1465
276. Bertino EM Phase IB study of Osimertinib in combination with Navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR Therapy (ETCTN 9903) Clin. Cancer Res. J. Am. Assoc. Cancer Res. 2021 27 1604 1611 10.1158/1078-0432.CCR-20-4084
Bertino, E. M. et al. Phase IB study of Osimertinib in combination with Navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR Therapy (ETCTN 9903). Clin. Cancer Res. J. Am. Assoc. Cancer Res. 27, 1604–1611 (2021).10.1158/1078-0432.CCR-20-4084
277. Joly F A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study Gynecol. Oncol. 2022 165 30 39 10.1016/j.ygyno.2022.01.021 35123771
Joly, F. et al. A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study. Gynecol. Oncol. 165, 30–39 (2022).35123771 10.1016/j.ygyno.2022.01.021
278. Zhu J Yang Q Xu W Iterative upgrading of small molecular Tyrosine Kinase Inhibitors for EGFR mutation in NSCLC: Necessity and perspective Pharmaceutics 2021 13 1500 10.3390/pharmaceutics13091500 34575576
Zhu, J., Yang, Q. & Xu, W. Iterative upgrading of small molecular Tyrosine Kinase Inhibitors for EGFR mutation in NSCLC: Necessity and perspective. Pharmaceutics 13, 1500 (2021).34575576 10.3390/pharmaceutics13091500
279. Clotworthy M The application of human tissue for drug discovery and development Expert Opin. Drug Discov. 2012 7 543 547 10.1517/17460441.2012.689282 22657575
Clotworthy, M. The application of human tissue for drug discovery and development. Expert Opin. Drug Discov. 7, 543–547 (2012).22657575 10.1517/17460441.2012.689282
280. Sun Y-K Progress in the treatment of drug-induced liver injury with natural products Pharmacol. Res. 2022 183 106361 10.1016/j.phrs.2022.106361 35882295
Sun, Y.-K. et al. Progress in the treatment of drug-induced liver injury with natural products. Pharmacol. Res. 183, 106361 (2022).35882295 10.1016/j.phrs.2022.106361
281. Dasari S Njiki S Mbemi A Yedjou CG Tchounwou PB Pharmacological effects of Cisplatin combination with natural products in cancer chemotherapy Int. J. Mol. Sci. 2022 23 1532 10.3390/ijms23031532 35163459
Dasari, S., Njiki, S., Mbemi, A., Yedjou, C. G. & Tchounwou, P. B. Pharmacological effects of Cisplatin combination with natural products in cancer chemotherapy. Int. J. Mol. Sci. 23, 1532 (2022).35163459 10.3390/ijms23031532
282. Ai X Efficacy and safety of Niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, Phase 3 study J. Thorac. Oncol. Publ. Int. Assoc. Study Lung Cancer 2021 16 1403 1414
Ai, X. et al. Efficacy and safety of Niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, Phase 3 study. J. Thorac. Oncol. Publ. Int. Assoc. Study Lung Cancer 16, 1403–1414 (2021).
283. Wang S Zimmermann S Parikh K Mansfield AS Adjei AA Current diagnosis and management of small-cell lung cancer Mayo Clin. Proc. 2019 94 1599 1622 10.1016/j.mayocp.2019.01.034 31378235
Wang, S., Zimmermann, S., Parikh, K., Mansfield, A. S. & Adjei, A. A. Current diagnosis and management of small-cell lung cancer. Mayo Clin. Proc. 94, 1599–1622 (2019).31378235 10.1016/j.mayocp.2019.01.034
284. Vinogradova M An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells Nat. Chem. Biol. 2016 12 531 538 10.1038/nchembio.2085 27214401
Vinogradova, M. et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat. Chem. Biol. 12, 531–538 (2016).27214401 10.1038/nchembio.2085
285. Fan J GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer J. Hematol. Oncol. J. Hematol. Oncol. 2023 16 77 10.1186/s13045-023-01467-9 37475048
Fan, J. et al. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer. J. Hematol. Oncol. J. Hematol. Oncol. 16, 77 (2023).37475048 10.1186/s13045-023-01467-9
286. Mullen MM GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress Mol. Cancer Res. MCR 2022 20 265 279 10.1158/1541-7786.MCR-21-0302 34670865
Mullen, M. M. et al. GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress. Mol. Cancer Res. MCR 20, 265–279 (2022).34670865 10.1158/1541-7786.MCR-21-0302
287. Kawakami R ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer Cancer Sci. 2020 111 962 973 10.1111/cas.14316 31960523
Kawakami, R. et al. ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer. Cancer Sci. 111, 962–973 (2020).31960523 10.1111/cas.14316
288. Li Y PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells Cancer Res 2023 83 398 413 10.1158/0008-5472.CAN-22-2370 36480196
Li, Y. et al. PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells. Cancer Res 83, 398–413 (2023).36480196 10.1158/0008-5472.CAN-22-2370
289. Wang L Dissection of mechanisms of Chinese medicinal formula Realgar- Indigo naturalis as an effective treatment for promyelocytic leukemia Proc. Natl Acad. Sci. 2008 105 4826 4831 10.1073/pnas.0712365105 18344322
Wang, L. et al. Dissection of mechanisms of Chinese medicinal formula Realgar- Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl Acad. Sci. 105, 4826–4831 (2008).18344322 10.1073/pnas.0712365105
290. Bondi A Dietz CC Penicillin resistant staphylococci Proc. Soc. Exp. Biol. Med. 1945 60 55 58 10.3181/00379727-60-15089 21004029
Bondi, A. & Dietz, C. C. Penicillin resistant staphylococci. Proc. Soc. Exp. Biol. Med. 60, 55–58 (1945).21004029 10.3181/00379727-60-15089
291. Law LW Some aspects of drug resistance in neoplasms Ann. N. Y. Acad. Sci. 1958 71 976 993 10.1111/j.1749-6632.1958.tb46817.x 13583865
Law, L. W. Some aspects of drug resistance in neoplasms. Ann. N. Y. Acad. Sci. 71, 976–993 (1958).13583865 10.1111/j.1749-6632.1958.tb46817.x
292. Welch AD The problem of drug resistance in cancer chemotherapy Cancer Res 1959 19 359 371 13652119
Welch, A. D. The problem of drug resistance in cancer chemotherapy. Cancer Res 19, 359–371 (1959).13652119
293. Yoshida T The nature of acquired drug resistance Cancer Chemother. Rep. 1961 13 123 128 13787394
Yoshida, T. The nature of acquired drug resistance. Cancer Chemother. Rep. 13, 123–128 (1961).13787394
294. Kinoshita T Nagai H Murate T Saito H CD20-negative relapse in B-cell lymphoma after treatment with Rituximab J. Clin. Oncol. 1998 16 3916 9850038
Kinoshita, T., Nagai, H., Murate, T. & Saito, H. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. J. Clin. Oncol. 16, 3916 (1998).9850038
295. Kobayashi S EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2005 352 786 792 10.1056/NEJMoa044238 15728811
Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).15728811 10.1056/NEJMoa044238
296. Clark J Cools J Gilliland DG EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head PLoS Med 2005 2 e75 10.1371/journal.pmed.0020075 15736989
Clark, J., Cools, J. & Gilliland, D. G. EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. PLoS Med 2, e75 (2005).15736989 10.1371/journal.pmed.0020075
297. Pao W KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2005 2 e17 10.1371/journal.pmed.0020017 15696205
Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2, e17 (2005).15696205 10.1371/journal.pmed.0020017
298. Glickman MS Sawyers CL Converting cancer therapies into cures: lessons from infectious diseases Cell 2012 148 1089 1098 10.1016/j.cell.2012.02.015 22424221
Glickman, M. S. & Sawyers, C. L. Converting cancer therapies into cures: lessons from infectious diseases. Cell 148, 1089–1098 (2012).22424221 10.1016/j.cell.2012.02.015
299. Zhao X BCL2 Amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models Cancer Cell 2019 35 752 766.e9 10.1016/j.ccell.2019.04.005 31085176
Zhao, X. et al. BCL2 Amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models. Cancer Cell 35, 752–766.e9 (2019).31085176 10.1016/j.ccell.2019.04.005
300. Kwok H-H Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma Cancer Commun. Lond. Engl. 2023 43 951 955 10.1002/cac2.12449
Kwok, H.-H. et al. Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma. Cancer Commun. Lond. Engl. 43, 951–955 (2023).10.1002/cac2.12449
301. Wang H C-IGF1R encoded by cIGF1R acts as a molecular switch to restrict mitophagy of drug-tolerant persister tumour cells in non-small cell lung cancer Cell Death Differ. 2023 30 2365 2381 10.1038/s41418-023-01222-0 37689814
Wang, H. et al. C-IGF1R encoded by cIGF1R acts as a molecular switch to restrict mitophagy of drug-tolerant persister tumour cells in non-small cell lung cancer. Cell Death Differ. 30, 2365–2381 (2023).37689814 10.1038/s41418-023-01222-0
302. Raoof S Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer Oncogene 2019 38 6399 6413 10.1038/s41388-019-0887-2 31324888
Raoof, S. et al. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene 38, 6399–6413 (2019).31324888 10.1038/s41388-019-0887-2
303. Chen M Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse Cell Rep. Med. 2024 5 101471 10.1016/j.xcrm.2024.101471 38508142
Chen, M. et al. Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. Cell Rep. Med. 5, 101471 (2024).38508142 10.1016/j.xcrm.2024.101471
304. Garcia, N. M. G. et al. APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer. BioRxiv Prepr. Serv. Biol. 2023.07.02.547443 10.1101/2023.07.02.547443 (2023).
305. Wen L Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review PloS One 2013 8 e59154 10.1371/journal.pone.0059154 23533603
Wen, L. et al. Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. PloS One 8, e59154 (2013).23533603 10.1371/journal.pone.0059154
306. Liu C ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression Cancer Res 2021 81 5919 5934 10.1158/0008-5472.CAN-21-1337 34580061
Liu, C. et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Res 81, 5919–5934 (2021).34580061 10.1158/0008-5472.CAN-21-1337
307. Chen W-C Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin Int. J. Oncol. 2016 49 1881 1889 10.3892/ijo.2016.3691 27633757
Chen, W.-C. et al. Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin. Int. J. Oncol. 49, 1881–1889 (2016).27633757 10.3892/ijo.2016.3691
308. Wang L Zuo X Xie K Wei D The Role of CD44 and cancer stem cells Methods Mol. Biol. Clifton NJ 2018 1692 31 42 10.1007/978-1-4939-7401-6_3
Wang, L., Zuo, X., Xie, K. & Wei, D. The Role of CD44 and cancer stem cells. Methods Mol. Biol. Clifton NJ 1692, 31–42 (2018).10.1007/978-1-4939-7401-6_3
309. Asakura N Expression of cancer stem cell markers EpCAM and CD90 is correlated with anti- and pro-oncogenic EphA2 signaling in hepatocellular carcinoma Int. J. Mol. Sci. 2021 22 8652 10.3390/ijms22168652 34445353
Asakura, N. et al. Expression of cancer stem cell markers EpCAM and CD90 is correlated with anti- and pro-oncogenic EphA2 signaling in hepatocellular carcinoma. Int. J. Mol. Sci. 22, 8652 (2021).34445353 10.3390/ijms22168652
310. Yang X Inhibition of DEC2 is necessary for exiting cell dormancy in salivary adenoid cystic carcinoma J. Exp. Clin. Cancer Res. CR 2021 40 169 10.1186/s13046-021-01956-0 33990215
Yang, X. et al. Inhibition of DEC2 is necessary for exiting cell dormancy in salivary adenoid cystic carcinoma. J. Exp. Clin. Cancer Res. CR 40, 169 (2021).33990215 10.1186/s13046-021-01956-0
311. Ohta Y Cell-matrix interface regulates dormancy in human colon cancer stem cells Nature 2022 608 784 794 10.1038/s41586-022-05043-y 35798028
Ohta, Y. et al. Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature 608, 784–794 (2022).35798028 10.1038/s41586-022-05043-y
312. Zhang M Nanog mediated by FAO/ACLY signaling induces cellular dormancy in colorectal cancer cells Cell Death Dis. 2022 13 159 10.1038/s41419-022-04606-1 35177584
Zhang, M. et al. Nanog mediated by FAO/ACLY signaling induces cellular dormancy in colorectal cancer cells. Cell Death Dis. 13, 159 (2022).35177584 10.1038/s41419-022-04606-1
313. Borgen E NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients Breast Cancer Res. 2018 20 120 10.1186/s13058-018-1049-0 30322396
Borgen, E. et al. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Res. 20, 120 (2018).30322396 10.1186/s13058-018-1049-0
314. Zhang W The eIF4A Inhibitor Silvestrol Blocks the Growth of Human Glioblastoma Cells by Inhibiting AKT/mTOR and ERK1/2 Signaling Pathway J. Oncol. 2022 2022 4396316 35677890
Zhang, W. et al. The eIF4A Inhibitor Silvestrol Blocks the Growth of Human Glioblastoma Cells by Inhibiting AKT/mTOR and ERK1/2 Signaling Pathway. J. Oncol. 2022, 4396316 (2022).35677890
315. Hashimoto A Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer Cell Commun. Signal. CCS 2021 19 54 10.1186/s12964-021-00733-y 34001163
Hashimoto, A. et al. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer. Cell Commun. Signal. CCS 19, 54 (2021).34001163 10.1186/s12964-021-00733-y
316. Cho Y-H 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation Nat. Commun. 2020 11 5321 10.1038/s41467-020-19173-2 33087710
Cho, Y.-H. et al. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation. Nat. Commun. 11, 5321 (2020).33087710 10.1038/s41467-020-19173-2
317. Liu Y Mechanisms and inhibition of Porcupine-mediated Wnt acylation Nature 2022 607 816 822 10.1038/s41586-022-04952-2 35831507
Liu, Y. et al. Mechanisms and inhibition of Porcupine-mediated Wnt acylation. Nature 607, 816–822 (2022).35831507 10.1038/s41586-022-04952-2
318. Thacker G Immature natural killer cells promote progression of triple-negative breast cancer Sci. Transl. Med. 2023 15 eabl4414 10.1126/scitranslmed.abl4414 36888695
Thacker, G. et al. Immature natural killer cells promote progression of triple-negative breast cancer. Sci. Transl. Med. 15, eabl4414 (2023).36888695 10.1126/scitranslmed.abl4414
319. Okura N ONO-7475, a Novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer Clin. Cancer Res. 2020 26 2244 2256 10.1158/1078-0432.CCR-19-2321 31953310
Okura, N. et al. ONO-7475, a Novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer. Clin. Cancer Res. 26, 2244–2256 (2020).31953310 10.1158/1078-0432.CCR-19-2321
320. Post SM AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia Haematologica 2022 107 1311 1322 10.3324/haematol.2021.278369 34732043
Post, S. M. et al. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica 107, 1311–1322 (2022).34732043 10.3324/haematol.2021.278369
321. Ruvolo PP Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms Haematologica 2017 102 2048 2057 10.3324/haematol.2017.168856 28912176
Ruvolo, P. P. et al. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. Haematologica 102, 2048–2057 (2017).28912176 10.3324/haematol.2017.168856
322. Xu S KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2 Blood Adv. 2021 5 3241 3253 10.1182/bloodadvances.2020002819 34448811
Xu, S. et al. KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2. Blood Adv. 5, 3241–3253 (2021).34448811 10.1182/bloodadvances.2020002819
323. Xue X-J Li F-R Yu J Mitochondrial pathway of the lysine demethylase 5C inhibitor CPI-455 in the Eca-109 esophageal squamous cell carcinoma cell line World J. Gastroenterol. 2021 27 1805 1815 10.3748/wjg.v27.i16.1805 33967558
Xue, X.-J., Li, F.-R. & Yu, J. Mitochondrial pathway of the lysine demethylase 5C inhibitor CPI-455 in the Eca-109 esophageal squamous cell carcinoma cell line. World J. Gastroenterol. 27, 1805–1815 (2021).33967558 10.3748/wjg.v27.i16.1805
324. Dinavahi SS Development of a novel multi-Isoform ALDH inhibitor effective as an antimelanoma agent Mol. Cancer Ther. 2020 19 447 459 10.1158/1535-7163.MCT-19-0360 31754071
Dinavahi, S. S. et al. Development of a novel multi-Isoform ALDH inhibitor effective as an antimelanoma agent. Mol. Cancer Ther. 19, 447–459 (2020).31754071 10.1158/1535-7163.MCT-19-0360
325. Mohapatra D Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF-β-induced tumor-associated fibrosis Lab. Investig. J. Tech. Methods Pathol. 2022 102 298 311 10.1038/s41374-021-00690-7
Mohapatra, D. et al. Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF-β-induced tumor-associated fibrosis. Lab. Investig. J. Tech. Methods Pathol. 102, 298–311 (2022).10.1038/s41374-021-00690-7
326. Ni Y-L Disulfiram/Copper suppresses cancer stem cell activity in differentiated thyroid cancer cells by inhibiting BMI1 expression Int. J. Mol. Sci. 2022 23 13276 10.3390/ijms232113276 36362068
Ni, Y.-L. et al. Disulfiram/Copper suppresses cancer stem cell activity in differentiated thyroid cancer cells by inhibiting BMI1 expression. Int. J. Mol. Sci. 23, 13276 (2022).36362068 10.3390/ijms232113276
327. Wang W An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer Mol. Cancer 2022 21 106 10.1186/s12943-022-01579-9 35477569
Wang, W. et al. An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer. Mol. Cancer 21, 106 (2022).35477569 10.1186/s12943-022-01579-9
328. Dai S Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine Biomed. Pharmacother. 2020 121 109521 10.1016/j.biopha.2019.109521 31689601
Dai, S. et al. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Biomed. Pharmacother. 121, 109521 (2020).31689601 10.1016/j.biopha.2019.109521
329. Pattni BS Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG Int. J. Pharm. 2017 532 149 156 10.1016/j.ijpharm.2017.08.095 28844900
Pattni, B. S. et al. Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. Int. J. Pharm. 532, 149–156 (2017).28844900 10.1016/j.ijpharm.2017.08.095
330. Huang X Gan G Wang X Xu T Xie W The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance Autophagy 2019 15 1258 1279 10.1080/15548627.2019.1580105 30786811
Huang, X., Gan, G., Wang, X., Xu, T. & Xie, W. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy 15, 1258–1279 (2019).30786811 10.1080/15548627.2019.1580105
331. Hu J ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine J. Exp. Clin. Cancer Res. CR 2019 38 225 10.1186/s13046-019-1201-4 31138329
Hu, J. et al. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine. J. Exp. Clin. Cancer Res. CR 38, 225 (2019).31138329 10.1186/s13046-019-1201-4
332. Zhai B Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review Biomed. Pharmacother. 2019 114 108812 10.1016/j.biopha.2019.108812 30965237
Zhai, B. et al. Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review. Biomed. Pharmacother. 114, 108812 (2019).30965237 10.1016/j.biopha.2019.108812
333. Jiang X-Y Shi L-P Zhu J-L Bai R-R Xie T Elemene antitumor drugs development based on ‘Molecular Compatibility Theory’ and clinical application: a retrospective and prospective outlook Chin. J. Integr. Med. 2024 30 62 74 10.1007/s11655-023-3714-0 37882911
Jiang, X.-Y., Shi, L.-P., Zhu, J.-L., Bai, R.-R. & Xie, T. Elemene antitumor drugs development based on ‘Molecular Compatibility Theory’ and clinical application: a retrospective and prospective outlook. Chin. J. Integr. Med. 30, 62–74 (2024).37882911 10.1007/s11655-023-3714-0
334. Zhang R β-Elemene reverses the resistance of p53-deficient colorectal cancer cells to 5-Fluorouracil by inducing pro-death autophagy and Cyclin D3-dependent cycle arrest Front. Bioeng. Biotechnol. 2020 8 378 10.3389/fbioe.2020.00378 32457882
Zhang, R. et al. β-Elemene reverses the resistance of p53-deficient colorectal cancer cells to 5-Fluorouracil by inducing pro-death autophagy and Cyclin D3-dependent cycle arrest. Front. Bioeng. Biotechnol. 8, 378 (2020).32457882 10.3389/fbioe.2020.00378
335. Kukcinaviciute E Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116 J. Cell. Biochem. 2018 119 5913 5920 10.1002/jcb.26783 29637602
Kukcinaviciute, E. et al. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116. J. Cell. Biochem. 119, 5913–5920 (2018).29637602 10.1002/jcb.26783
336. Wang Z Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell Int. J. Phytother. Phytopharm. 2021 82 153414
Wang, Z. et al. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell. Int. J. Phytother. Phytopharm. 82, 153414 (2021).
337. Li X Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents Eur. J. Med. Chem. 2019 179 667 679 10.1016/j.ejmech.2019.06.086 31279299
Li, X. et al. Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents. Eur. J. Med. Chem. 179, 667–679 (2019).31279299 10.1016/j.ejmech.2019.06.086
338. Li N Discovery of semisynthetic celastrol derivatives exhibiting potent anti-ovarian cancer stem cell activity and STAT3 inhibition Chem. Biol. Interact. 2022 366 110172 10.1016/j.cbi.2022.110172 36096161
Li, N. et al. Discovery of semisynthetic celastrol derivatives exhibiting potent anti-ovarian cancer stem cell activity and STAT3 inhibition. Chem. Biol. Interact. 366, 110172 (2022).36096161 10.1016/j.cbi.2022.110172
339. Moreira H Celastrol and Resveratrol Modulate SIRT Genes Expression and Exert Anticancer Activity in Colon Cancer Cells and Cancer Stem-like Cells Cancers 2022 14 1372 10.3390/cancers14061372 35326523
Moreira, H. et al. Celastrol and Resveratrol Modulate SIRT Genes Expression and Exert Anticancer Activity in Colon Cancer Cells and Cancer Stem-like Cells. Cancers 14, 1372 (2022).35326523 10.3390/cancers14061372
340. Ye T Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion Biomed. Pharmacother. 2016 82 319 326 10.1016/j.biopha.2016.05.015 27470369
Ye, T. et al. Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion. Biomed. Pharmacother. 82, 319–326 (2016).27470369 10.1016/j.biopha.2016.05.015
341. Park I-J Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation Cancer Lett. 2010 298 88 98 10.1016/j.canlet.2010.06.006 20638780
Park, I.-J. et al. Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett. 298, 88–98 (2010).20638780 10.1016/j.canlet.2010.06.006
342. Hyun SY Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70 Theranostics 2021 11 2932 2952 10.7150/thno.49876 33456581
Hyun, S. Y. et al. Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70. Theranostics 11, 2932–2952 (2021).33456581 10.7150/thno.49876
343. Fan X Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma Bioorg. Chem. 2021 114 105154 10.1016/j.bioorg.2021.105154 34378540
Fan, X. et al. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma. Bioorg. Chem. 114, 105154 (2021).34378540 10.1016/j.bioorg.2021.105154
344. Wang J Ma Y Guo M Yang H Guan X Salvianolic acid B suppresses EMT and apoptosis to lessen drug resistance through AKT/mTOR in gastric cancer cells Cytotechnology 2021 73 49 61 10.1007/s10616-020-00441-4 33505113
Wang, J., Ma, Y., Guo, M., Yang, H. & Guan, X. Salvianolic acid B suppresses EMT and apoptosis to lessen drug resistance through AKT/mTOR in gastric cancer cells. Cytotechnology 73, 49–61 (2021).33505113 10.1007/s10616-020-00441-4
345. Guo P Salvianolic acid B reverses multidrug resistance in HCT‑8/VCR human colorectal cancer cells by increasing ROS levels Mol. Med. Rep. 2017 15 724 730 10.3892/mmr.2016.6049 28000873
Guo, P. et al. Salvianolic acid B reverses multidrug resistance in HCT‑8/VCR human colorectal cancer cells by increasing ROS levels. Mol. Med. Rep. 15, 724–730 (2017).28000873 10.3892/mmr.2016.6049
346. Guo P Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells Mol. Med. Rep. 2018 18 1323 1334 29845279
Guo, P. et al. Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells. Mol. Med. Rep. 18, 1323–1334 (2018).29845279
